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Interaction of monoclonal antibodies with the immune
system
M. Clark, R. Benjamin, C. Bindon, M. Bruggeman,
S. Cobbold, L. Gilliland, G. Hale, S. Qin, H. Tighe
& H. Waldmann
Department ofPathology, University ofCambridge,
UK.
We have been deriving rat monoclonal antibodies
directed against human cell surface antigens for
therapeutic use. In parallel to this work we have
also derived antibodies against mouse cell surface
antigens for use in model systems of human sero-
therapy. A number of conclusions can be made.
1. Rat monoclonal antibodies can be derived
which exploit the natural effector mechanisms such
as human complement, ADCC and cytotoxic T-cells.
2. CAMPATH-1, a human complement fixing
rat IgM specific for human lymphocytes is able to
eliminate lymphocytes from bone marrow and
hence reduce the incidence and severity of GVHD.
3. Rat IgG2b antibodies are able to mediate
ADCC with human K-cells.
4. Suitable pairs of rat IgG2b antibodies
synergise in complement lysis.
5. Rat IgG2b antibodies to mouse T-cell subsets
eliminate cells in vivo and cause marked immuno-
suppression of T-cell mediated responses.
6. Serotherapy with anti-(mouse T-cell) antibodies
can facilitate the reconstitution of sub-lethally
irradiated mice with T-cell depleted mismatched
marrow grafts.
7. Rat antibodies to the mouse L3/T4 antigen
are capable of inducing tolerance to rat and human
immunoglobulin.
8. Mice which have been rendered tolerant to rat
IgG2b are still capable of making an anti-idiotype
response to cell-binding antibodies. The exceptions
to this are antibodies to the L3/T4 antigen.
9. The anti-idiotype response in tolerised mice
has implications for human serotherapy with
human or chimeric monoclonal antibodies.
The Ca antigen
H. Harris
Sir William Dunn School ofPathology, University of
Oxford, UK.
The Ca antigen was detected by screening matched
pairs of hybrid cells, one member of which was
malignant and the other not. The antigen was
found on the malignant, but not on the non-
malignant hybrid cells, and was later detected in a
wide range of human malignant tumours. The
expression of the antigen in the tumours varied in
intensity. In some cases there was generalised
labelling of virtually all the malignant cells in the
tumour; in other cases the labelling was patchy.
The antigen was also found on a number of normal
epithelia, notably the urothelium, the luminal
surfaces of the epithelia of the oviduct, apocrine
sweat glands, the ducts of eccrine sweat glands and
of the epididymis, and the trophoblast of the
developing embryo. A totally unexpected finding
was the presence of the antigen on Type II
pneumocytes, for which it appears to be specific.
Monoclonal antibodies directed against the Ca
antigen have found some clinical usefulness in
diagnostic cytology, but the main interest lies in the
antigen itself. Substantial chemical characterisation
of the antigen has been achieved, and it has turned
out to be a mucin to which the name EPITECTIN
has been given. A most remarkable characteristic of
this mucin is that it is inducible in vitro by high
concentrations of sodium lactate. Detailed analysis
of the induction by lactate has provided strong
evidence that the basic effect is on osmolarity. The
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antigen is induced when the osmolarity of the
surrounding medium is substantially increased. It is
likely that lactate is the physiological agent
involved in the body, although other substances
may achieve the same effect in vitro. More recent
studies in vivo will also be reported.
Recombinant antibodies for clinical use
mouse antibody B1-8 which binds the hapten
NP-cap (4-hydroxy-3-nitrophenacetyl-caproic acid;
KNP-P = 1.2,M) to replace the corresponding
CDRs of a human myeloma protein. We find that in
combination with the B1-8 mouse light chain, the
new antibody has acquired the hapten affinity of
the B1-8 antibody KNP-cPa= 1.9MM). Such 'CDR
replacement' may offer a way of constructing
human monoclonal antibodies from the correspond-
ing mouse monoclonals.
M.W. Bodmer
Celltech Ltd., Bath Road, Slough SLI 4DY, Berks,
UK.
Interest in the clinical use of monoclonal antibodies
has created a demand for techniques to tailor
immunoglobulin molecules to make best use of
their specificity and binding properties. Recom-
binant DNA techniques provide great flexibility
in joining combining domains with cytotoxic or
biological effector functions which may be better
suited to in vivo use than natural immunoglobulin
molecules or fragments. We can 'humanise' anti-
bodies, create well-defined fragments, incorporate
specific labelling sites and generate protein-protein
fusions. In addition, by interchanging combining
sites we can make fairly homogeneous sets of
reagents directed at a variety of tumour markers.
Work is in progress in our laboratory on
isolation and manipulation of genes encoding a
number of antibodies specific for colon and ovarian
tumour markers. In parallel we are developing gene
expression systems to allow high level expression of
recombinant material.
Replacing the complementarity-determining regions
in a human antibody with those from a mouse
J. Foote, P.T. Jones, P. Dear, M.S. Neuberger &
G. Winter
Medical Research Council Laboratory ofMolecular
Biology, Hills Road, Cambridge CB2 2QH, UK.
The hypervariable domains of an antibody consist
of a fl-sheet framework with hypervariable regions
(or complementarity-determining regions - CDRs)
which fashion the antigen binding site. Can the
antigen site be transplanted from one framework to
another by grafting the CDRs? We have used the
CDRs from the heavy chain variable region of
Monoclonal antibodies to oncogene products
K. Sikora, G. Evan, S. Chan, J. Stewart &
J. Watson
Department ofClinical Oncology, Royal
Postgraduate Medical School, Hammersmith
Hospital and Ludwig Institutefor Cancer Research,
MRC Centre, Cambridge CB2 2QU, UK.
The demonstration that unique segments for DNA,
constant in location and conserved in evolution, are
involved in growth control opens new avenues for
clinical research. The function of these oncogenes
and their relevance to specific disease processes
needs to be elucidated. The function of the
products of several oncogenes has now been
determined; in all cases it is related to growth
control.
To evaluate the clinical significance of abnormal
gene expression, monoclonal antibodies have been
constructed to several human oncoproteins. These
include c-myc, c-sis, c-ras, c-myb and N-myc. We
have studied archival material from patients with
testicular, breast and colorectal cancer by immuno-
histology and flow cytometric analysis of isolated
nuclei. We have compared expression of the c-myc
gene with that of c-ras and related expression levels
to the histological differentiation state of the
tumour. In colorectal cancer, it is clear that benign
polyps and well-differentiated tumours express
c-myc in greatest abundance. Poorly differentiated
tumours express lower levels in the testis, semi-
nomas have the highest level of c-myc expression
with undifferentiated rapidly growing tumours the
least. We have related c-myc expression histo-
logically to flow cytometric analysis using isolated
nuclei from paraffin blocks. Good correlation exists
between both sets of data. Our findings suggest
that the c-myc oncogene product may play an
important role in the evolution of neoplasia.
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oncoprotein levels may provide potentially useful
information for patient care.
Leucocyte-associated antigens
G. Janossy
Monoclonal antibody imaging and therapy of solid
tumours
Department ofImmunology, Royal Free Hospital
School ofMedicine, London NW3 2QG, UK.
S.M. Larson
Nuclear Medicine Department, National Institutes of
Health, Bethesda, MD, USA.
We used 1311-labelled Fab fragments of antibodies
for diagnosis in malignant melanoma. A sensitivity
of 88%, and a specificity of 100% was observed in
selected patienits. A Phase I trial of treatment of
malignant melanoma was begun, using high dose
radiolabelled anti-p97 and anti-chondroitin sulphate
proteoglycan FABs. We found that we could target
multiple doses of therapeutic MOABs to human
tumours safely. Among 3 patients who received
more than 450mCi, 2 had an anti-tumour response
- one a prolonged stabilisation, and a second a
partial regression. A more extensive trial is
currently underway. Toxicity is seen as marrow
suppression at one month post-treatment. This
predictable radiation effect has not resulted in
severe clinical side-effects.
B72.3 is an immunoglobulin that recognises
TAG-72, a high molecular weight mucin-like
compound that is produced by breast, ovarian and
colon cancers. We studied 25 patients with colon
cancer to determine localisation after intravenous
administration of 13 I-labelled B72.3. All the
patients underwent surgical exploration after injec-
tion of the radiolabelled MOAB. If tumour/normal
tissue ratio of >3.0 is taken as a cut-off, 85% of
tumours were positive. Also, patients were co-
injected with a non-specific 1251-labelled antibody
of the same sub-class. Ratios of specific to non-
specific ranged from 2.5-10.0. Gamma camera
imaging showed excellent targeting to lesions, which
was most favourable at one week post-injection.
B72.3 labelled 1311 was injected i.p. in 5 patients
with pseudomyxoma peritonei. All patients had
excellent localisation which correlated well with
subsequent surgical findings. Clearance from the
tumour site was prolonged, with a T-1/2 of >4.0
days. In 3 of the 5 patients, CT scans of the
abdomen were negative, at a time when the imaging
study was positive. Thus, the radiolabelled antibody
detected disease not evident with other methods.
Localisation of antibody to lesions was avid, with
maximum concentrations of 0.18% injected dose
per gram of tumour. Dosimetry is favourable for
therapy.
Leucocyte typing workshops have established
panels of monoclonal antibodies to leucocyte
antigens leading to the standardisation of the
diagnosis of leukaemias and lymphomas. A number
of antibodies have distinct therapeutic possibilities;
(i) mismatched haploidentical bone marrow trans-
plantation (BMT) and (ii) autologous BMT.
(i) The tissue reactivity of HLFA (human
leucocyte functional antigen; CD18) has been
established. HLFA appears on the B cell lineage at
the pre-B cell stage and in the T lineage on the
large thymic blasts but is absent on TdT+ B cell
precursors and on myeloid and erythroid precursor
cells. As this antibody is efficient in blocking
leucocyte function, it is suggested that it could be
infused around the time of transplantation to
patients receiving mismatched BM in order to
promote the 'take' of haploidentical BM. BM
regeneration in these haploidentical BMTs has been
rapid. Further studies are warranted to study anti-
HLFA in BMT for leukaemia.
(ii) A sensitive assay has been developed and is
used in the MRC UKALL-X trials in order to
establish the lytic efficacy of McAbs of IgM class
against common ALL T-ALL and B cell
lymphomas. This assay is based on restaining
residual blasts following C lysis with an
independent marker such as nuclear TdT (C-ALL
and T-ALL) and anti-immunoglobulin (B
lymphoma). We can get greater than 4log kill in
75% of the malignancies with rabbit complement
and, surprisingly, in 50% of cases with autologous
human complement. Suitable antibodies for this
purpose are: RFAL3 (CD1O; IgM, human
complement fixing), RFB7 (CD20; IgM, human
complement fixing), SB4 (CD19; IgM, partially
human complement fixing, and RFT2 (CD7; IgG2,
rabbit complement fixing).
Patterns of expression of keratins and mucins by
mammary epithelial cells
J. Taylor-Papadimitriou1, S. Gendlerl, J. Burchell'
& J. Bartek2
1Imperial Cancer Research Fund, Lincoln's Inn
Fields, London WC2A 3PX, UK; and 2Res. Inst.
Clin. Exp. Oncol., Zluty Kopec 7, 602 00 Brno,
Czechoslovakia.
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produced by most epithelial cells have been used to
define differentiation phenotypes in epithelial cell
lineages and to relate these to the malignant
phenotype. The first are the keratins which make
up the intermediate filaments of epithelial cells and
the second are mucin-like molecules, i.e. glyco-
proteins containing a high proportion of 0-linked
sugars. The monospecific and pleurispecific anti-
bodies to keratins have been useful in defining
cell lineages and characterising the malignant
phenotype in terms of these lineages in the
mammary gland. Antibodies to the mucin-like
molecules (which can be expressed on the cell
membrane) are widely used for detecting carcinoma
cells and their products in body tissues and fluids
and for localising tumours in patients. Molecular
and immunological .analysis of the large glyco-
proteins shows a size heterogeneity, some of
which is attributable to genetic polymorphism.
Preliminary results with a cDNA probe corres-
ponding to part of the gene coding for the core
protein of the mucin expressed by breast cancer
cells show that the expression of this gene is indeed
only seen in epithelial cells. Antibodies reactive
with the core protein but not with the fully pro-
cessed mucin react with breast cancers, but not
normal breast epithelium suggesting that there may
be incomplete processing of the mucin in some
cancers.
HLA antigens in human tumours
M. Moore
Department ofImmunology, Paterson Laboratories,
Christie Hospital and Holt Radium Institute,
Manchester M20 9BX, UK.
The status of human tumours with respect to the
expression of the major histocompatibility complex
(MHC) antigens is amenable to analysis by
immunocytochemical techniques using monoclonal
antibodies directed against heavy (a) and light
(f2m) chain class I (HLA-A,B,C) molecules and
sub-locus products (DP, DQ, DR) of the HLA-D
region. The expression of these molecules has
implications both for the inductive and effector
phases of the anti-tumour immune response. Class I
expression, common to virtually all nucleated
normal cells, is reduced or lost in a significant
proportion of primary epithelial cancers, especially
of the breast, and could conceivably represent a
mechanism by which tumour cells evade T cell
recognition. Class II expression, previously thought
to be largely restricted to cells of the immune
system, may also be a constitutive property of some
normal epithelia, but is most readily detectable on
tissues - normal, inflamed, premalignant and
malignant - undergoing hormonal or immune
stimulation. In certain epithelia (e.g. small intestine)
the function of class II molecules is to present
antigen to T helper cells, but in some tumour
systems (e.g. malignant melanoma) a depressive
effect in the ability of primary tumours to stimulate
autologous T lymphocytes has been reported. These
findings indicate that the class II status of tumour
cells has important functional implications for the
tumour-host relationship.
Uses of immunohistopathology
D.Y. Mason & K.C. Gatter
Nuffield Department ofPathology, University of
Oxford, UK.
Monoclonal antibodies are now of clearly
established value in the immunocytochemical
investigation of tumours of uncertain origin. The
principal antibodies in this context are those against
leucocyte common antigen and against cytokeratin,
although anti-epithelial membrane antigen also has
a role to play. Antibodies of these specificities
which give good staining reactions on paraffin
sections are now available. Use of these reagents
should be mandatory whenever anaplastic
morphology or poor tissue preservation make it
difficult to reach a histological diagnosis.
A further use of immunocytochemistry in clinical
oncology is in the detection of metastatic spread.
Carcinomatous infiltration of lymph nodes may be
detected by staining for epithelial markers, even
when these cells are not visible by conventional
microscopy. The method may also be applied to
bone marrow smears, serous effusions and fine
needle aspirates.
Finally, a novel application of monoclonal
antibody immunohistology involves the use of
antibody Ki-67 (directed against a proliferation-
associated antigen), to assess the growth rate, and
hence possible clinical behaviour, of tumours.
A review of antigens of milk fat globule membranes
and their value for diagnosis and prognosis of breast
cancer
J. Hilgers
Division of Tumour Biology, The Netherlands Cancer
Institute, 1066 CX Amsterdam, The Netherlands.
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be purified in large quantities from fresh human
milk and represent the apical surface of the fully
mature lumenal cell of the mammary gland. Many
cell surface proteins in these membranes are not or
hardly at all expressed in tumours of the mammary
gland, but some are and these may be useful for
diagnosis and prognosis of human breast cancer.
The so-called MAM-3 and MAM-6 group of
antigens representing determinants of the HMFGM
are found in the cell surface of breast cancer cells
(Hilkens et al., Int. J. Cancer, 34, 197, 1984).
MAM-3 antigens appear to belong to antigens
closely related to Lewis blood group 'a' and 'b'
substances (Gool et al., Biochem. Biophys. Res.
Comm., 131, 543, 1985; Gool et al., in press).
MAM-6 group antigens are expressed on a family
of mucins of very high molecular weight.
Monoclonal antibodies against the MAM-3
group were used to see whether they are of
prognostic value in predicting the course of breast
cancer, e.g. in relation to presence and absence of
steroid hormone receptors (Rasmussen et al.,
Cancer Res., 45, 1424, 1985).
Monoclonal antibodies against the MAM-6
group of antigens are useful as markers for the
epithelial nature of tumours and indicators for a
'carcinoma' (Zotter et al., Virchovs Archiv A., Path.
Anat., 466, 237, 1985) in the blood, because they
are shed into the circulations (Hilkens et al., Cancer
Res., in press).
A new marker for breast cancer. Use in
immunohistochemical studies on formalin-fixed,
paraffin-embedded tissues and at the electron
microscope level
R. Mandeville, L. Giroux, F. Dumas, S. Fhali,
B. Grouix, M.C. Zelechowska & I. Ajdukovic
Institut Armand-Frappier, University ofQuebec,
LDR, Quebec, Canada J7E 4B9.
A series of monoclonal antibodies (MAs) showing a
different spectrum of reactivity to human mammary
tissues of normal and neoplastic origin have
recently been described (In Monoclonal Antibodies:
Diagnostic and Therapeutic Use in Tumour and
Transplantation, S.N. Chatterjee (ed) p. 63. PSB
Publishing Co. Inc., Littleton, Mass., 1985). Studies
on frozen sections of mammary tumours using
indirect immunofluorescence (IF) enabled us to
select one monoclonal antibody, namely lF1OB4
that recognises a cytoplasmic determinant highly
expressed in most of the primary and metastatic
breast carcinomas studied, and weakly (or not at
all) in normal breast and non-breast tissues. More
recently, we have compared its reactivity in frozen,
acetone-fixed tissues using IF and formalin-fixed,
paraffin-embedded sections using a standard
avidin-biotin peroxidase technique. lF1OB4 reacted
with 11 of the 21 primary tumours studied,
demonstrating that in 52% of the cases, the
antigenic determinant(s) detected on frozen acetone-
fixed tissues were preserved after fixation in
formalin. Moreover, localisation of breast cancer
associated antigens recognised by lF1OB4 was per-
formed by electron microscopy in Lowicryl K4M
thin sections using a modified protein A-gold
technique. This technique allowed the demon-
stration that lFlOB4 reacts with determinant(s)
mainly expressed in the cytoplasm, only few
reactivities were observed at the cell surface and
on microvilli. This monoclonal antibody should be
ofbiological, pathological and clinical value.
A new monoclonal antibody (OVTL3) against human
ovarian carcinoma that does not react with
circulating tumour antigens
L.G. Poels & P. Kenemans
Departments ofCytology & Histology and
Gynaecology, Medical Faculty, University of
Nijmegen, Geert Grooteplein N21, 6500 HB
Nijmegen, The Netherlands.
A cell suspension prepared from an ovarian
endometrioid carcinoma was used to immunise
BALB/c mice. Following a fusion protocol with
PEG 4000 and the myeloma cell line Sp2/0-Ag 14,
the hybridoma supernatants were screened by an
immunofluorescence assay on cryostat sections of
ovarian carcinomas and colon carcinomas. The
selected clone (OVTL3) produced IgG1 monoclonal
antibody that did bind to freshly obtained cryostat
sections and methanol fixed ascitic tumour cell
clusters. The MoAb, however, did not bind to any
paraffin processed tissue. The antibody reacted with
>95% of the epithelial ovarian tumours (serous,
mucinous, endometrioid and clear cell type); weak
focally with 3 (14) endometrial carcinomas;
negative with non-ovarian gynaecological tumours;
negative with all other carcinomas. OC125
antibodies reacted with 85% of the ovarian
carcinomas in this study, in both the serum assay
and immunohistochemical assay. The use of radio-
iodinated OVTL3 in a sandwich serum assay did
not result in any binding of antigen in serum with
high titres of CA125, neither was any binding
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OC125. From these studies, it appeared that
OVTL3 did not detect circulating ovarian
carcinoma antigens nor did it bind to different
epitopes of the CA125 molecule. Binding to
OVTL3 could only be achieved using freshly
prepared Ov.Ca. extracts. SDS treatment abolished
the binding activity. These results indicate that
OVTL3 might be a good marker for histodiagnosis
of ovarian cancer. The absence of binding to serum
antigens might indicate that the OVTL3 could be
useful for in vivo imaging and targeting therapy, as
also suggested by the observation that the antibody
remained bound for at least 24h on cultured
Ov.Ca. cells.
MOv18 and MOvl9: Two new monoclonal
antibodies with restricted specificity against human
ovarian carcinoma
S. Menard, S. Canevari, S. Miotti, E. Tagliabue &
M.I. Colnaghi
Istituto Nazionale Tumori, Via G. Venezian 1, 20133
Milan, Italy.
It has been demonstrated that ovarian carcinoma
cells express immunogenic high molecular weight
molecules in large quantities and it is against these
that most anti-ovarian carcinoma antibodies are
directed; however, similar molecules may also be
expressed to a lesser extent by normal epithelial
cells, thus creating problems concerning the
specificity of the antibody.
To obtain monoclonal antibodies with more
restricted specificities, we selected as immunogenic
source, an undifferentiated ovarian carcinoma
which was unreactive with previously obtained
antibodies. Two new antibodies (MOvl8 and
MOvl9) with similar patterns of reactivity were
selected. They both recognise about 80% of ovarian
carcinomas, but are negative with non-epithelial
tumours and normal tissues as tested by immuno-
fluorescence on frozen sections. In fact, reactivity
was observed in only 3 out of 120 cases of non-
ovarian carcinoma. Immunoprecipitation of radio-
iodinated membrane molecules from OVCa432 cells
indicated that the relevant antigen of the two
MoAbs is a 36-38mol. wt. protein. A double-
determinant assay demonstrated that MOv18 and
MOvl9 recognise two different epitopes on this
molecule.
Placental-type alkaline phosphatase in pre-invasive
cervical neoplasia
P.J. McLaughlin', G.E. Hutchinson',
P.M. Tromans2, A.S. Woodcock2 & P.M. Johnson'
Departments of 1Immunology and 2Obstetrics &
Gynaecology, University ofLiverpool, PO Box 147,
Liverpool L69 3BX, UK.
We studied the occurrence of placental-type
alkaline phosphatase in cervical intra-epithelial
neoplasia (CIN) with or without evidence of human
papilloma virus infection. Three approaches were
used, all utilising the monoclonal antibodies H317
and H17-E2 in enzyme immuno-assay as previously
described (McLaughlin et al., Clin. Chim. Acta, 130,
199, 1983). The first approach, detection of the
marker in sera, was uniformly negative. In contrast,
21/29 (72%) of solubilized cervical smears and
31/38 (82%) of solubilized biopsy specimens
contained detectable enzyme. However, there was
no correlation between placental-type alkaline
phosphatase levels and degree of dysplasia or
presence of HPV infection of the cervix. Neverthe-
less, the finding of mAb-reactive placental-type
alkaline phosphatase, sometimes at high levels
(>100Ukg-1 tissue) in cervical biopsy material
suggests the potential for these mAbs in radio-
imaging studies of metastatic or invasive cervical
carcinoma.
Purification and characterization of a tumour specific
genetically engineered murine/human chimeric
monoclonal antibody
B.A. Brown, G. Davis, J. Saltzgaber-Muller,
P. Simon, P.S. Shaw & G.P. Moore
E.L du Pont de Nemours, Co. Inc., No. Billerica,
MA, USA.
Human/murine chimeric MAbs may overcome the
limitation of host response to murine MAbs in the
diagnosis and treatment of human cancer. We have
previously produced a human/murine chimeric
MAb (cB6.2) containing the B6.2 variable region.
The transfectants were introduced into mice and
yielded about 200,ug of cB6.2ml-1 of ascites fluid.
The cB6.2 was purified by Protein A chromato-
graphy followed by anti-murine IgG Sepharose to
remove murine IgG originating from the ascites.
This yielded pure cB6.2 which resembled human
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and isoelectric point. In contrast, it resembled the
murine parent B6.2 in its antigenic behaviour in
competitive binding studies and immunofluorescent
cell staining. Analysis of immunoprecipitated
antigen yielded equivalent results for cB6.2 and
B6.2 (70-80,000mol. wt. protein from A549.El and
a heterogeneous set of proteins of 97-
180,000mol. wt. from SW900, both lung lines).
Finally, the two antibodies when radioiodinated
behaved identically when injected into athymic mice
bearing either LS174T (antigen specific) or HCT-15
(non-specific) tumours. Both MAbs imaged the
specific tumours and exhibited identical localisation
and clearance in the mice. With the excellent
retention of antigenic binding behaviour, as
demonstrated by cB6.2, similar murine/human
chimeric MAbs may be a useful improvement over
tumour-specific murine MAbs in the clinical setting.
Synthesis of l-(p-isothiocyanatobenzyl) DTPA.
Antibody labelling and tumour imaging studies in
comparison with DTPA anhydrides and EDTA
O.A. Gansow, M. Brechbiel, R.W. Atcher,
J. Scholm, D. Simpson, J. Esteban & D. Colcher
National Cancer Institute, Bethesda, MD 20892,
USA.
To investigate the '111In-labelling tumour-localising
monoclonal antibodies (MoAb), we have synthesized
the chelate 1-(p-isothiocyanatobenzyl)-diethylene-
triaminepentaacetic acid (p-SCN-BZ-DTPA) and
its EDTA analogue. By using a MoAb (B72.3)
specific for a high molecular weight antigen
(TAG-72) on cells of a colorectal carcinoma grown
in nude mice, optimal chemical conditions for
MoAb conjugation of those ligands and the dicyclic
and isobutylcarboxycarbonic anhydrides of DTPA
and subsequent "'In labelling were determined. All
conjugates were shown by a competitive binding
assay to retain their specificity and activity in vitro
both prior to and after "'In labelling when less
than one ligand is protein coupled.
Chemical methods for purification of the MoAb
were systematically investigated by injection of
purified immunoprotein into athymic mice bearing
LS-174T tumours which express the TAG-72
antigen. Tissue distribution studies revealed that
simple addition of EDTA to labelled IgGs was
ineffective at complexing indium not linked to
protein by chelates. Similarly, gel chromatography
(Sephadex G-50) was not sufficient, rather, size
exclusion HPLC had to be employed to remove
unreacted "'In and aggregated antibody.
To compare the relative utility of the 4 chelates
for "'In diagnostic radioimmunoimaging, scinti-
graphic images of tumour bearing mice were
obtained and evaluated along with tissue
distributions. Results showed that clear images of
these solid tissue tumours free of extraneous
radiation could be obtained only by using protein
coupled to p-SCN-BZ-DTPA and purified by
HPLC after "'In labelling. Methods developed are
now being modified for clinical trials for diagnosis
of human colorectal cancer.
Functionalised macrocycles- an alternative to
bifunctional chelates?
D. Parker, I. Helps & R. Morphy
Department ofChemistry, University ofDurham,
South Road, Durham DHI 3LE, UK.
Antibody-radionuclide conjugates may be used for
both imaging and therapy. Radioactive metal
complexes may be covalently attached to an
antibody without compromising antigen binding,
and the radionuclide is conventionally complexed
by an acyclic chelate (EDTA, DPTA or its
modified versions).
An alternative approach is to bind the metal ion
within a macrocyclic ligand, which is functionalised
both with ionisable groups (e.g. -CH2CO2H) to
facilitate metal binding and with a-bromoacetamide
or maleimide groups for coupling to an antibody.
Macrocyclic metal complexes are typically both
thermodynamically stable and kinetically inert to
metal decomplexation. The design and synthesis of
a series of functionalised macrocycles is reported,
together with some preliminary binding studies for
technetium, indium and yttrium.
Update on 1231 labelled antibodies
M. Granowska & K.E. Britton
Department ofNuclear Medicine, St. Bartholomew's
Hospital Medical College, University ofLondon and
Imperial Cancer Research Fund Laboratories,
London, UK.
1231 is a pure gamma-ray emitting radionuclide,
energy 159 KeV, which is appropriate for very
efficient detection by the gamma camera for radio-
immunoscintigraphy. It has a 13h half-life which
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allows good serial studies for 24h during the time
of maximum uptake of monoclonal antibody which
may be easily labelled using the chloramine T or
iodogen technique. 1231 is to be preferred to 1231
because present administered doses of 1311-labelled
antibodies give considerable statistical noise in the
images. Our original technique using 123I-labelled
monoclonal antibody of subtracting an early image
from a later one has been refined through kinetic
analysis of serial images with probability mapping.
On the assumption that tissue background is
decreasing with time and tumour uptake is
increasing with time, serial images may be
compared pixel by pixel and the frequency
distribution of activity plotted. Using a least
squares technique the clusters of pixels showing
significant positive or negative deviation with time
may be identified and the areas of significant
change at, for example, the P<0.001 plotted on a
map as a contour over the original data. In 23
patients 100 biopsy sites were correctly identified in
a blind study as tumour positive or negative for
ovarian cancer in 75% by the probability map, and
all patients with metastases (some subclinical and
X-ray CT negative) before second look operation
and 3 out of 4 patients without metastases were
correctly identified. Such identification of small
recurrences, preferably without a second look
operation, is a necessary prelude to successful intra-
peritoneal radioimmunotherapy.
Prospective immunoscintigraphic localisation of
recurrences of ovarian carcinomas using 1311_
OC125 F(ab')2 monoclonal antibody
J.F. Chatal, J.C. Saccavini, P. Fumoleau, C. Curtet,
M. Kremer, J.Y. Douillard & B. Le Mevel
Unite 211, INSERM and CRG, Nantes, and ORIS
Industrie, Saclay, France.
OC125 monoclonal antibody recognises an antigen
(CA125) associated with serous-type ovarian adeno-
carcinomas and shed by tumour cells into the
circulation. Radioiodinated (1311) F(ab')2 fragments
of this antibody were injected into 24 patients
previously operated on for a primary ovarian
carcinoma who had increasing serum concen-
trations for CA125 antigen, suggesting an otherwise
unsymptomatic recurrence. Each patient was
injected with 74-129.5 MBq using a specific activity
of 74MBqmg-1. A total of 34 immunoscinti-
graphic studies was performed in these 24 patients
using planar scintigraphy and/or SPECT imaging.
Two patients had a simultaneous injection of
131I-OC125 F(ab')2 and 125I-irrelevant immuno-
globulin F(ab')2 3 days before second look surgery,
and radioactivity was measured in tumour and
normal tissue specimens. Immunoscintigraphy
correctly localised a recurrence in 18 out of 24
(75%) cases. Based on the number of tested
anatomical sites, there were 23 true positive results,
13 false negative results, 50 true negative results
and 2 false positive results. Ultrasonography was
compared with immunoscintigraphy in 22 patients;
both methods were positive in 8 confirmed tumour
sites. Ultrasonography was positive and immuno-
scintigraphy was negative in 2 tumour sites and
immunosintigraphy was positive when ultrasono-
graphy was negative in 10 tumour sites.
The percentages of injected dose per gram of
tumour in the 2 patients studied were respectively
2.2 and 4.5 times higher with OC125 antibody than
with irrelevant immunoglobulin. Tumour to tissue
ratios ranged from 1.1 to 10.3. Immunoscintigraphy
was the only positive method in 4 patients allowing
curative surgical resection of the recurrence.
Antibodies labelled with "'In and 90Y for clinical
use
A.A. Epenetos
On behalf of the Royal Postgraduate Medical
School, London and Imperial Cancer Research Fund,
London, UK.
A monoclonal antibody (H17E2) against placental
alkaline phsophatase (PLAP) was labelled with
Indium-ill and used in radioimmunoscintigraphy
of 60 patients with carcinoma of ovary, cervix, and
testis. The results for this study confirmed earlier
pilot studies (Epenetos et al., Lancet, i, 350, 1985)
in that this method sliuld now be incorporated in
the panel of investigations used for the diagnosis,
staging and monitoring of PLAP-positive
neoplasms.
A new pilot study has recently commenced
examining the radioimmunolocalisation potential of
IIIIn-labelled F(ab')2 fragments of antibody
HMFG1 in breast and non-small cell lung cancer.
Results so far indicate a high degree of radio-
immunolocalisation but further data are required.
A new radiolabelled 90Yttrium has been chelated
to anti-PLAP antibody (H17E2) in view of the fact
that 90Y may be one of the best radionuclides for
tumour therapy (suitable half-life, pure beta-ray
emitter of intermediate energy, stable daughter). We
found that 90Y obtained from 90Sr generator is
suitable for antibody labelling, achieving specificABSTRACTS OF ORAL PRESENTATIONS 533
activities of 1-5mCimg-1. We found no significant
loss ofimmunoreactivity, as tested in radioimmuno-
assay, and no aggregate or breakdown product
formation as tested by HPLC. In vivo
biodistribution studies are currently in progress.
Binding of IgG, IgA and IgM to cationic proteins by
their Fc regions
R.N. Poston & S. Pambakian
Department ofHistopathology, UMDS, Guy's
Hospital, London SE] 9RT, UK.
A fundamental strong interaction is described that
occurs between the Fc region of all 3 major Ig
classes and cationic (basic) proteins.
Experimentally, it has been studied by solid
phase RIA between soluble Ig and solid phase basic
proteins. It is strongest with IgM, followed by IgA
and IgG. With IgG, it is greatly enhanced by
aggregation. The activity is present in isolated Fc,
but not in F(ab')2 fragments. It is inhibitable by
other serum proteins with varying efficacies, IgM
binding being the least affected. This phenomemon
is probably an analogue of the well-known binding
of Ig to ion exchange resins; and may form the
basis for many non-specific binding phenomena
shown by Ig, in vivo and in vitro. (R.N. Poston,
Lancet, i, 1268, 1984.)
Monoclonal antibodies against human neuroblastoma
and establishment of isotype-switch variants
S. Schonmann, C. d'Uscio, K. Walstra & K. Blaser
Laboratory ofMolecular Immunology, University of
Berne, Switzerland.
We have established a panel of monoclonal
antibodies (Mab) reacting with human neuro-
blastoma. By using 5 selected Mab, 3 types of
neuroblastoma cc ild be distinguished among cell
lines and solid tumours according to their binding
pattern. One of the Mab, designated as CE7,
specifically binds to all sympatho-adrenomedullary
cells. CE7 belongs to the IgGl/k class and does not
mediate C'-dependent lysis of neuroblastoma cells.
This was demonstrated by a 51Cr-release assay.
CE7 recognizes a glycoprotein of 190kd which
binds to lentil lectin. IMR-32 neuroblastoma cells
express 2 x 105-5 x 105 CE7-binding molecules on
their surface. The Mab CE7 is used for in vitro
diagnosis.
In order to generate Mab which display the same
epitope specificity but different effector functions,
we have isolated spontaneously arising y2a and y2b
isotype-switch variants from the CE7 hybridoma
line. By stepwise cloning and using a sensitive
isotype-specific sandwich ELISA y2b variants were
selected from the yl and y2a variants from the y2b
secreting line. The frequency of arising variants in
the yl and y2b hybridoma lines was 5.4 x 1O' and
5.0 x lo-, respectively. Revertants were not
detected. The 2 isotype switch variants retain the
binding specificity for neuroblastoma cells. In
contrast to CE7, the Mab AD2 being of IgM/k
class and recognizing an epitope exclusively
expressed on some but not all neuroblastoma cells,
is cytotoxic with normal human serum or guinea
pig complement. It may be used for lysis of tumour
cells in vitro, for example purging of bone marrow
from AD2-reactive neuroblastoma cells.
Immune complexes of OC125-CA125 following
intravenous injection of the radiolabelled monoclonal
antibody into ovarian cancer patients
H. Haisma, A. Battaile, R.C. Knapp &
V.R. Zurawski, Jr.
Gynaecological Oncology Laboratories, Department
ofObs. & Gynae., Harvard Medical School, and
Dana Farmer Cancer Institute, Boston, Mass, USA.
The monoclonal antibody OC125 binds to -80%
of epithelial ovarian cancers and has been used to
construct an immunoradiometric assay which
detects the antigenic determinant, CA125, in the
serum of ovarian cancer patients. Five ovarian
cancer patients with pre-injection serum CA125
levels of 150-9000Uml-1 were injected with 131-
labelled (1.2-1.9mCi) OC125 F(ab')2 (0.5-0.8mg)
labelled at a specific activity of 2.5 uCi,g-1. Using
gel filtration of the patients' sera, apparent immune
complexes were observed within 15min after
injection of the monoclonal antibody. By 5 days
after injection 0.25% of the OC125 antibody could
be detected in its native form. The rate of immune
complex formation and the amount of complexes
formed correlated well with the observed pre-
injection serum CA125 level. In vitro experiments
confirmed the correlation between complex
formation and CA125 level. We conclude,
therefore, that the complexes consist of CA125-
OC125 immune complex. Despite the presence of
serum immune complexes, 1311 labelled monoclonal
OC125 could be found localised in tumour tissue at
post-surgical examination by gamma counting.534 ABSTRACTS OF ORAL PRESENTATIONS
Tumour to surrounding tissue ratios were in excess
of 10-20. However, tumour to blood ratios never
exceeded 2. These findings were corroborated by
immunoperoxidase staining techniques.
Our study suggests that the presence of immune
complexes after injection of a monoclonal antibody
into cancer patients will have an impact on the use
of monoclonal antibody OC125 and other mono-
clonal antibodies reactive with serum antigens for
radioimmunodetection and for therapy.
Multicentre studies of immunoscintigraphy of the
Italian National Research Council
A.G. Siccardi
Dipartimento di Biologia e Genetica per le Scienze
Mediche, Universita Degli Studi di Milano, 20133
Milan, Italy.
The restricted tissue distribution of tumour-
associated antigens and the high degree of specifi-
city of the corresponding monoclonal antibodies
have been exploited for immunoradioimaging
procedures to visualise lesions in patients with solid
tumours. A multicentre study was performed to
analyse the efficacy of 99mTc- and 11'In-labelled
F(ab')2 fragments of monoclonal antibody 225.28S
(reactive with HMW-MAA, a high molecular
weight melanoma associated antigen) to radioimage
malignant lesions in patients with melanoma. A
total of 254 patients with melanoma, carrying 412
documented lesions, were studied in 10 centres. A
total of 377 lesions were visualised in 206 patients;
in particular, (i) 250/412 known lesions were
visualised in 151/191 patients known to have
melanoma lesions; (ii) 95 occult lesions were
visualised in 61 patients of the same group; (iii) 32
lesions were visualised in 15/63 patients without
diagnosed lesions. The melanoma nature of 101/127
radioimaged occult lesions was confirmed by
clinical criteria and/or by additional laboratory
investigations. The study has shown good
agreement in the results obtained by the 10 centres,
suggesting that immunoscintigraphy with radio-
labelled F(ab')2 fragments of the MoAb 225.28S is
a reliable procedure. In order to confirm the
efficacy of the immunoscintigraphic method,
another multicentre study, concerning 'Immuno-
scintigraphy for detection of metastases of
colerectal carcinoma through radiolabelled anti-
CEA monoclonal antibodies' has been started
recently.
Immunolymphoscintigraphy in breast cancer patients
N. Pateisky1, K. Philipp', C. Schatten1 &
R. Mandeville2
1Jst Department of Obstetrics & Gynaecology,
University of Vienna, A-1090 Vienna, Austria and
2Institut Armand-Frappier, University ofQuebec,
Canada J7E 4B9.
Subcutaneous application of radiolabelled antibody
seemed to us to be an appropriate way to examine
metastatic involvement of the lymphatics draining a
primary carcinoma. Using 3 different tumour-
associated monoclonal antibodies (known to react
strongly with breast carcinoma cells in vitro), we
investigated the axillary regions of 35 patients
suspected ofhaving breast cancer. Radioactive 1-123
was used as the label. The finger webs between
the second and third fingers served as injection
sites. Static images were taken up to 8h after the
application. Activity accumulation over the axilla
was used as an indicator for metastatic involve-
ment. In each of the patients antibodies were
injected on both sides. The difference in activity
accumulation (counts) over the axillary regions was
calculated. If the difference was statistically
significant, the scan was judged as positive. The
antibody 3C6F9 appeared to be the best. Out of 20
patients the results were correct in 18 (6 xnegative,
12 xpositive). The scan results were compared with
the histology of the surgically removed nodes and
data so far would indicate that the method of
immunolymphoscintigraphy may be of value in
staging patients with breast cancer.
Tumour imaging with "'In and 131I labelled
anti-CEA antibodies (BW 431/31)
J. Vanderick1, N. Leners2, A. Ferrant2,
C. Deckers' & G. Schulz3
'Exper. Cancer, 'Nucl. Med., University ofLouvain
Medical School, Brussels, Belgium and 3Res. Lab.,
Behringwerke AG, Marburg 1, FRG.
The murine anti-CEA monoclonal antibody
BW 431/31 (Bosslet et al., Int. J. Cancer, 36, 75,
1985) has been used in 10 patients. Eight had
colorectal carcinoma and 2 had elevated CEA of
unknown origin. The first 7 patients had injection
of 0.5mg monoclonal antibody (Mab), and the 3
others received 3mg. In 6 patients, intact Mab was
given and in 4 F(ab')% fragments. BW 431/31 wasABSTRACTS OF ORAL PRESENTATIONS 535
labelled with 1I11n in 8 patients and with 1311 in 2
patients. Scintigrams were performed 24, 48, 72
and, in 3 patients, 96h after injection. In 3 out of 8
patients with colorectal carcinoma, the findings of
radioimmunoscintigraphy and CT scan were in
agreement. In 3 other patients, in apparent clinical
remission, sites of abnormal uptake were seen. Two
patients had bulky necrotic masses. No uptake was
observed in one and a slight uptake in the other. In
2 patients with elevated CEA of unknown origin,
the radioimmunoscintigrams were negative. No
side-effects were observed after injection of the
Mabs. In 3 patients, activity was observed at the
site of the kidneys after injection of labelled F(ab')2
fragments. Radioimmunoscintigraphy using
BW 431/31 may give correct information on the
localisation of colorectal carcinoma. Adequate
uptake can be observed from 24h after injection.
F(ab')2 fragments provided better defined images
than those obtained with intact Mab and the
quality was further enhanced with 1111n labelling.
Further work is needed to show if there is an
advantage in using 3mg instead of 0.5mg Mab.
The effect of increasing unlabelled monoclonal
antibody (MoAb) doses on metastases detection and
on body distribution of various "'In MoAbs
L.M. Lamkil, T.P. Haynie1, J.L. Murray1,
R. Babaian1, Y.Z. Patt' & B. Merchant2
1Department ofNuclear Medicine, MD Anderson
Hospital, Houston TX 77030 and 2Hybritech Inc.,
CA, USA.
We have studied 4 different murine MoAbs, all
labelled with 5mCi of 11In. These include 96.5
(anti-P97, melanoma), ZME-018 (anti-high
molecular weight antigen of melanoma), ZCE-025
(anti-CEA) and PAY-276 (anti-prostatic acid
phosphatase). Twenty to 25 patients were studied
using each MoAb. In each study, patients were
divided into groups of 5 patients according to the
amount of unlabelled MoAb injected with the 1 mg
111In-labelled MoAb. Unlabelled MoAb dose
varied from 1 mg to 80mg. Images, digital and
analogue, were acquired at 24, 72 and in most cases
at 120 and 168h. Lesion detection was compared
with clinical, radiographic and other scintigraphic
results. Regions of interest were used to analyse
relative non-tumour body distribution of labelled
MoAb at 72h.
In all 4 MoAb results, detection rate of
metastatic lesions improved with increasing MoAb
dose but the 'saturation' point differed with each of
them, ranging from 20 to 80mg.
The non-tumour body distribution also varied
with increasing MoAb dose. The liver uptake fell as
the bone, kidney and blood pool increased with
increasing MoAb dose. The level at which statistical
significance occurred, however, varied with each
antibody. Spleen uptake was variable.
The 'blocking' effect of unlabelled MoAb
influences the non-specific distribution of labelled
MoAb primarily through reduction of liver uptake
and increases the sensitivity of metastases detection.
Anti-tumour effects of immunotoxins in vitro and in
vivo
P.E. Thorpe, E.J. Wawrzynczak, D.C. Blakey &
F. Stirpe
Imperial Cancer Research Fund, Lincoln's Inn Fields,
London WC2, UK.
A panel of immunotoxins was prepared by linking
monoclonal anti-Thyl.1 antibody with the SPDP
reagent to the A-chains of ricin or abrin or to 3
ribosome-inactivating proteins which act in
analogous fashion: saporin, bryodin and
Momordica charantia inhibitor (MCI).
Cytotoxicity. The immunotoxins were specifically
toxic to Thyl.1-espressing AKR-A lymphoma cells
in tissue culture. The concentrations of immuno-
toxin that reduced protein synthesis by 50% ranged
between 10-11M for the abrin A immunotoxin and
0-9 M for the MCI immunotoxin.
Antitumour activity. Mice bearing peritoneal
AKR-A lymphoma cells were given a single i.v.
injection of 0.3nmol of immunotoxin. The
extension in median survival time ranged from 6
days for the abrin A immunotoxin (corresponding
to 99% tumour cell kill) to 24 days for the saporin
and bryodin immunotoxins (corresponding to
99.999% tumour cell kill).
Linkage. The low antitumour activity of the
abrin A immunotoxin could be rectified by
changing the crosslinker from SPDP to 2-imino-
thiolane. This is because - 1% of AKR-A cells
survive exposure to the SPDP-linked immunotoxin
(both in vitro and in vivo) but are killed by the 2-
iminothiolane-linked immunotoxin. It is possible
that the resistant cells have elevated levels of an
enzyme capable of splitting the amide bond in the
SPDP linkage. Both the SPDP and 2-iminothiolane
linkages break down slowly in vivo (T- =8h),
probably because the disulphide bond is unstable.536 ABSTRACTS OF ORAL PRESENTATIONS
A new coupling agent, SMBT, has been made
which avoids this problem.
Reticuloendothelial recognition. Ricin A immuno-
toxins are cleared in vivo by the reticuloendothelial
cells of the liver. These cells have receptors for the
oligosaccharide portion of ricin A-chain. Deglyco-
sylation of the A-chain with metaperiodate and
cyanoborohydride prevents clearance of the
immunotoxin by the reticuloendothelial system.
Pathology. Linkage of saporin and abrin A-chain
to immunoglobulin increases their toxicity to mice
by 10-20 fold. Both immunotoxins cause extensive
hepatic necrosis whereas neither saporin nor abrin
A-chain in unconjugated form cause significant
liver damage.
Drug-antibody conjugates for cancer therapy
R.W. Baldwin
Cancer Research Campaign Laboratories, University
ofNottingham, Notts. NG7 2RD, UK.
Conjugation of cytotoxic drugs to antibody aims to
introduce the maximum number of residues whilst
retaining acceptable retention of both drug and
antibody reactivities. This will be considered with
respect to the design of conjugates in which mono-
clonal antibody 791T/36 has been directly linked to
a range of anti-cancer agents including metho-
trexate, daunomycin and vindesine; drug activity
being evaluated by in vitro cytotoxicity assays and
antibody by a flow cytometry assay developed to
precisely define the antibody potency in conjugates.
In general only a limited number of drug residues
can be linked to antibody and in order to increase
the drug-antibody combining ratio drug-carrier
systems have been developed. This will be
considered with respect to the design of metho-
trexate-human serum albumin 791T/36 monoclonal
antibody conjugates. This has increased the
drug:antibody ratio to 30-40:1, so increasing the
potency of the conjugates.
Therapy trials with MTX conjugated to
monoclonal antibody 791T/36 have shown that
they suppress growth of human tumour xenografts
in immunodeprived mice. Furthermore, the
antibody binds to target cells derived from primary
and metastatic colorectal carcinomas. These studies
will be considered with respect to be design of
clinical trials with methotrexate conjugates.
Antibody-kemptide conjugate: A novel method
for the 32p labelling of monoclonal antibodies
B.M.J. Foxwell, H. Bond, G. Watson, D. Snook,
J. Long, W. Jeffery, P. Parker, A.A. Epenetos,
P. Thorpe & A. Creighton
Imperial Cancer Research Fund, Lincoln's Inn Fields,
London WC2 and Royal Postgraduate Medical
School, London W12, UK.
In recent years, radiolabelled monoclonal anti-
bodies have been evaluated for their use in the
diagnosis and treatment of neoplastic disease. One
isotope which has not been assessed for antibody
targeting is 32P, even though this isotope has many
favourable radiobiological characters and has been
used clinically for the treatment of certain
neoplastic disorders. The main drawback so far in
using 32P has been the absence of a general method
for phosphorylating antibodies. We have now
developed a novel process for the phosphorylation
of immunoglobulins which is rapid, efficient and
allows for high specific activities to be achieved
(>1lyCi g-1). The technique involves the
chemical conjugation of Kemptide, a synthetic
septapeptide substrate for kinases, to immuno-
globulins. The antibody-kemptide conjugate is then
able to act as a substrate for protein kinases. The
conjugation procedure does not compromise the
binding activity of the antibody. Studies have
shown that 32P-labelled monoclonal antibodies are
stable in human, mouse and rat plasmas in vitro.
We are now assessing the in vivo clearance of
kemptide-antibody conjugates and the efficacy of
using 32P as an antibody-targeted isotope.
Potential value of intrahepatic 1311-ethiodol in
patients with hepatocellular carcinoma
C.H. Park1, J.H. Suh2, H.S. Yoo2, J.T. Lee2 &
D.I. Kim2
'Division ofNuclear Medicine, Thomas Jefferson
University Hospital, Philadelphia, USA and
2Department ofRadiology, Yan-Sei University
Hospital, Seoul, Korea.
The specific aim of the study was to evaluate
therapeutic feasibility of radiolabelled iodized oil
injected into the hepatic artery proper on patients
with hepatocellular carcinoma (HCC).
In a recent study, Ethiodol (or Lipiodol), which
is an iodized poppy seed oil, was selectivity retained
in the tumour vessels of large HCC in the liver forABSTRACTS OF ORAL PRESENTATIONS 537
long periods following injection into the hepatic
artery.
Recently, we replaced with 1311 a small quantity
(pg) of the stable iodine of the 37% iodine by
weight in Ethiodol with 100% exchange efficiency.
Patients with HCC were injected with 131[-
Ethiodol through the hepatic artery. The agent was
stable for 8 days in vivo and there was no
significant activity in the thyroid gland, stomach,
lung. Urine and blood activity was negligible. There
was a high tumour to normal liver ratio for up to 8
days post-injection indicating that 1311-Ethiodol
will be effective delivering high internal radiation
dose to the HCC.
Activation of human complement by covalent
conjugates of mouse monoclonal antibodies and cobra
venom factors
B. Miiller, H. Harpprecht, M.J.D. Anderson & W.
Muller-Ruchholtz
Abt. Immunologie, Universitat Kiel, D-2300 Kiel,
FRG.
For T-cell depletion in allogeneic bone marrow
transplantation it is highly desirable to use
antibodies or, rather, antibody conjugates which
activate human complement (C), since unspecific
toxicity of rabbit sera against human stem cells is
usually high
Methods: Two different monoclonal antibodies
(MoAb; KI36 directed against a monomorphic
HLA DR determinant and K39A6 directed against
a determinant on human lymphocytes) were
conjugated to cobra venom factor (CVF) using the
heterobifunctional reagent SPDP. The cytotoxic
potential of the non-modified MoAbs and the
conjugates against human leukaemia cell lines and
lymphocytes from different organs was estimated in
a 5'-Chromium release assay, comparing rabbit and
human sera as source ofC.
Results: (1) While K136 does not fix C, the
conjugate KI36/CVF lyses specifically cells which
express HLA DR. (2) K39A6 lyses lymphocytes in
presence of rabbit C, but is ineffective with human
C at any concentration tested. (3) The conjugate
K39A6/CVF activates rabbit C at least as well as
K39A6 alone. Furthermore, it initiates very
efficiently human C dependent cytolysis. (4) CVF-
initiated cytolysis, using the alternative pathway of
C activation, is slower than Ab-initiated lysis via
the classical pathway and reaches maximal killing
of target cells after 4h. These data show that it is
possible to use mouse Ab for killing human
lymphocytes with autologous C by bonding it
covalently to CVF.
Selective insertion of 32p into immunoglobulins by
protein kinases
F.R. Burnet1, C.G. Proud1, T. Williams1,
A. Richardson2, E. Heyderman3, P. Mountford2 &
A. Coakley2
1Biological Laboratory, University ofKent at
Canterbury, 2Department ofNuclear Medicine, Kent
& Canterbury Hospital, 3Department of
Histopathology, St. Thomas's Hospital, London SEJ,
UK.
Radiolabelled tumour directed immunoglobulins
have great potential as a means of both locating
and treating solid tumours and their metastases.
The radiochemical properties of 32P make it a good
candidate as a therapeutically useful isotope with
which to tag immunoglobulins. We have tested the
ability of cyclic AMP dependent protein kinase
(cAMP dep PK), Casein Kinase II and Protein
Kinase C to phosphorylate both a pan-reactive
anti-,B tubulin mouse monoclonal (IgG, type 2B,
KMX-1) and a selection of polyclonal IgG fractions
from different animals. One of them was rabbit
anti-prostatic acid phosphatase (anti-PAP) which is
undergoing clinical evaluation in the imaging of
the metastases of prostate tumours. None of
the kinases were capable of inserting 32P from
[y-32P]ATP into the native immunoglobulins, but
cAMP dep PK was found to be capable of
phosphorylating all of the immunoglobulins tested
after their partial denaturation in urea. This
denaturation was found to be reversible.
Stoichiometry Of 32Pmol inserted per mol IgG
ranged from 0.1 for KMX-1 to 1 for anti-PAP. We
are now extending our studies to discover the
optimal denaturation condition for phosphorylation
and the factors which determine this denaturation's
reversibility in immunoglobulins phosphorylated in
different domains.
Immunoscintigram with monoclonal antibodies of
liver metastases of colorectal cancer
R.G.E. Holzheimer, K.H. Muhrer, H. Muller &
K. Bosslet
Departments ofGeneral Surgery and Nuclear
Medicine, Justus-Liebig-Universitat, Giessen and
Behringwerke AG, D-3550, Marburg 1, FRG.
In a pretherapeutic study we examined the value of538 ABSTRACTS OF ORAL PRESENTATIONS
intra-arterial infusion of CEA-specific monoclonal
antibody in 13 patients with liver metastases from
colorectal cancer. In these patients a catheter was
implanted in the hepatic artery for regional chemo-
therapy. Monoclonal antibody (Tu MAK BW
431/31) binds specifically to CEA. The antibody
was labelled with 131I. During the 1 h infusion, we
observed and documented the distribution kinetics
of the monoclonal antibody. We performed a
control scintigram after 24h, 2 and 3 days.
Localisation and distribution of the metastases were
verified by CT scan. In 9 of 13 patients we could
see distinctive enhancement of activity in metastatic
lesions during the 1 h intra-arterial infusion. These
enhancements resembled defects in the 99Tc-colloid
scintigram. The control scintigram showed less
enhancement at 24 or 48h after infusion of activity
but by 72h there was again increased uptake in the
metastases. The positive visualisation of metastases
after 1 h infusion lets us conclude that by intra-
arterial infusion this monoclonal antibody binds
quickly to the tumour.
Immunoscintigraphy of lung carcinoma: Experience
in 45 patients
P. Riva, G. Paganelli, G. Riciputi, G. Pasini,
S. Benini, M. Agostini, G. Moscatelli,
G. Cacciaguerra, V. Tison, P. Morigi &
V. Stancanelli
Istituto Oncologico Romagnolo, 47023 Cesena, Italy.
The most widely studied tumours employing mono-
clonal antibodies (MoAb) are those of the gastro-
intestinal tract, skin (mainly melanoma) and female
genital tract. In vivo studies in patients with lung
cancer are very few. We decided to carry out an in
vivo phase I study, since we found positive staining
in 80% of tissue sections from lung cancer using
the MoAb F023C5 against CEA. No positive
results were obtained either in vitro and in vivo
when we used, as negative control, a non-specific
MoAb raised against the HMW MAA (melanoma-
associated antigen).
Thirty-three patients with squamous carcinoma, 8
with oat cell carcinoma and 4 with chronic
pulmonary disease were studied by means of "1In
and/or 131I-labelled F(ab')2 fragments of the above-
mentioned MoAb.
The antibody scan visualised 27 out of 31
primary tumours (87%) and 25 out of 30
documented metastatic lesions. No positive scan
was obtained in any patient with non-neoplastic
pulmonary disease.
In addition, we succeeded in detecting occult
metastases not diagnosed by conventional
radiology. Best images were obtained with 111n-
labelled MoAb at 72h after i.v. injection. The
tumour to background ratio obtained in vivo by
means of ROI technique, and in vitro, employing a
multichannel system, was better when 111In label
was used and ranged between 2.3 to 4.7.
Intra-tumoral distribution of labelled antibodies and
fragments. Autoradiography of tumour-bearing nude
mice
S. Matzku, B. Gamer & W. Tilgen
Institute ofNuclear Medicine, Deutsches
Krebsforschungszentrum and Department of
Dermatology, University ofHeidelberg, FRG.
To get access into solid tissue, antibody molecules
have to cross the endothelial lining and the
basement membrane of peripheral vessels, followed
by translocation in the extravascular space. In the
tumour tissue, the blood-tissue barrier may be leaky
to a variable degree, thus providing a surplus of
antibody influx. Yet, strategies to improve access
are badly needed. To characterise changes in
antibody penetration into tumour tissue, we
performed whole body autoradiography of mice
with melanoma transplants, systematically looking
at the following variables: morphotype of
melanoma line, intra-tumoral blood volume,
penetration of irrelevant MAb, penetration of
various anti-melanoma MAbs, accumulation time,
fragment size (i.e. intact IgG, F(ab')2, Fab).
It was observed that all tumour lines showed a
surprisingly poor blood supply and diffuse
distribution of irrelevant IgG. With MAbs known
to exhibit significant uptake in the paired label
assay, a highly inhomogeneous activity distribution
was obvious in all tumours, activity being deposited
in close vicinity to supplying blood vessels. With
both types of fragments, whole body autoradio-
graphy confirmed the well known fact of rapid
clearance of radioiodinated species from the
organism, and it revealed an obvious increase in the
permeation of radioactivity throughout the tumour
node, thus reaching areas of low blood input, too.ABSTRACTS OF ORAL PRESENTATIONS 539
The effect of second antibody in the
radioimmunotherapy of colorectal cancer
J.A. Ledermann, R.H.J. Begent, S.R. Riggs,
P. Keep, F. Searle, A.J. Green, M.G. Glaser,
R.J. Dale & K.D. Bagshawe
CRC Laboratories, Department ofMedical
Oncology, Charing Cross Hospital, London W6 8RF,
UK.
We have used a 'second antibody' directed against
the radiolabelled anti-tumour antibody in order to
establish if the background radioactivity and there-
fore potential toxicity to normal tissues can be
reduced. Six patients with advanced colorectal
carcinoma were given 40-55mCi 131I labelled sheep
anti-CEA (2.5mg) and 3 patients received 'second
antibody' donkey anti-sheep (10mg) 24h later.
Radioactivity cleared more rapidly in those
receiving 'second antibody', the majority appearing
in the urine and < I% in the faeces. Measurements
of the dose received by the tumour and normal
tissues were made to assess whether the accelerated
clearance of anti-tumour antibody could enhance
the therapeutic ratio.
In total 11 patients have been treated with either
goat or sheep anti-CEA. There were few side-
effects: 7/11 developed transient chills and fever; no
cases of myelosuppression, impaired renal or
hepatic function were seen. Using ELISA human
anti-goat antibody was demonstrated prior to
treatment in 2 patients and developed in a further
6. Antibodies were not detected in those patients
who did not receive 'second antibody'. The tumour
could be visualised by scintigraphy in 10 patients
and was histologically confirmed in 4/5. An
objective response was seen in 2 patients; a fall in
CEA and CA19-19 levlels and improvement in pain
for one month in one and a reduction in the size of
an hepatic metastasis on CT in another. A further 2
patients had an improvement in pain. These results
demonstrate the potential benefit of second
antibody and the safety of this dose level. However,
immunisation of the host against antibodies is a
significant problem and may limit the potential for
repeated therapy.
Dosimetry of radiolabelled antibodies
P.K. Leichner
The Johns Hopkins Oncology Centre, Baltimore,
Maryland 21205, USA.
Optimisation of radiolabelled antibody cancer
therapy in clinical trials depends on dosimetry for
radiation dose estimates, choice of antibodies and
activities to be administered and the timing of
administrations. The necessary data are acquired by
quantitative imaging and image analysis of X-ray
CT and SPECT scans as well as planar gamma
camera images. Semi-automatic computer software
has been developed to compute tumour and normal
organ volumes from CT and SPECT scans and for
the in vivo quantitation of radiolabelled antibody
activities in these volumes from conjugate gamma
camera views. Additionally, computerised
volumetrics are used to assess tumour response to
therapy. Comparison with autopsy data has shown
that computerised CT volumetrics of primary
hepatic cancers are an accurate (±6%) and
reproducible way to determine volumes non-
invasively. Phantom studies indicate that the
accuracy of in vivo quantification of "'1In activities
ranges from 0.9 to 9%, depending on volumes and
activities being imaged.
This methodology is being used clinically in an
ongoing Phase 1-2 trial of radiolabelled antiferritin
IgG in hepatoma. "'In-labelled antiferritin is used
as the imaging agent to calculate 90Y antiferritin
activities to be administered to achieve pre-
determined tumour absorbed doses and at the same
time reduce toxicity to normal tissues. Labelling
ratios of 90Y antiferritin have ranged from 10-
40mCimg-1 and administered activities from 8-
37mCi. Tumour dose rates of up to 38cGyh-'
have been achieved after external-beam tumour
irradiation of 600cGy or 900cGy.
Regional antibody therapy
A.A. Epenetos
On behalfofRoyal Postgraduate Medical School,
London and Imperial Cancer Research Fund,
London, UK.
Following the demonstration (Epenetos et al.,
Lancet, i, 1441, 1984) that monoclonal antibody
targeted radiotherapy may prove a valuable form of
treatment in certain situations, at least when it is
delivered into body cavities and regions rather than
intravenously, we expanded our studies in various
areas.
1. A randomised multicentre clinical trial using
radioactively labelled monoclonal antibodies for the
treatment of stage III minimal residual disease
ovarian cancer has recently been initiated, following
the completion of a phase I-II study where data
were obtained regarding toxicity and response.540 ABSTRACTS OF ORAL PRESENTATIONS
2. Following the completion of a trial involving
intracavity administration of antibodies in the
treatment of serous effusion (12 responders out of
15 patients), a randomised study has commenced of
I3'I-labelled specific vs. non-specific antibody
administered on an out-patient basis.
3. Six patients with grade III/IV glioma of brain
having relapsed after radiotherapy + chemotherapy
have received intra-arterial infusions of '311-labelled
monoclonal antibody (EGFR1, against epidermal
growth factor receptor) as a therapeutic attempt.
Four out of 6 patients responded favourably with
clinical and radiological improvement.
4. Monoclonal antibodies to carcinoembryonic
antigen (CEA) were radiolabelled with 1311 and
administered intra-arterially (via the hepatic artery)
concurrently with biodegradable starch micro-
spheres in order to enhance tumour uptake of
antibody and achieve a therapeutic response.
Favourable results were observed in one patient
treated thus far. A pilot study has recently
commenced examining the potential therapeutic
effect of this approach in patients with small size
(<2cm diam.) liver metastases.
Analysis of the human anti-mouse Ig response in
patients receiving murine monoclonal antibodies
M.A. Ritter, N.S. Courtenay-Luck, M. Larche,
B. Dhokia, G. Sivolapenko & A.A. Epenetos
Departments ofImmunology and Clinical Oncology,
Royal Postgraduate Medical School, London, UK.
The use of mouse monoclonal antibodies in the
diagnosis and therapy of malignant neoplasms is of
considerable clinical interest. However, a
consequence of such treatment is the stimulation of
a human immune response to the injected mouse
immunoglobulins. Prolonged monoclonal antibody
treatment leads to an elevation of this response,
resulting in an increased risk of Type III immune
complex mediated hypersensitivity. An under-
standing of the underlying immune mechanisms
involved in the development of the human anti-
mouse Ig response is clearly of importance if such
side effects are to be avoided.
We have studied the anti-mouse Ig response in
ovarian carcinoma patients who have received both
diagnostic and therapeutic injections of 1311-
labelled mouse monoclonal antibodies. The
following parameters have been analysed:
(a) pre-existing antimouse Ig antibodies, prior to
treatment;
(b) location of the antigenic determinants on
mouse Ig to which the response is directed;
(c) the prozone effect obtained with high titre
sera and its implications in routine clinical assays;
(d) the development of anti-tumour antibodies
during monoclonal antibody treatment;
(e) the possible risk of autoimmune reactions.
Primary ocular melanoma: Evaluation with
radioimmunoscintigraphy
K. Scheidhauer, F. Stefani, A. Markl,
U. Schumacher & E. Moser
Departments ofRadiology, Ophthalmology and
Anatomy, University ofMunich, 8000 Munich 70,
FRG.
Radioimmunoscintigraphy of cutaneous malignant
melanoma has been reported in several clinical
trials, mostly in patients with multiple metastases
and extended lesions. This study was undertaken to
evaluate the potential of radioimmunoscintigraphy
in small lesions.
Therefore, 9 patients suffering from primary
ocular melanoma were investigated. The average of
lesions' prominence was 6.7mm (range: 3.5-
10.8mm), proved by opthalmoscopy and ultra-
sound. RIS was performed 18h post-injection of
99mTc-labelled F(ab')2 fragments (350Mg) of an
IgG2a monoclonal antibody (225.28S) - developed
by Ferrone et al. and supplied as a ready-to-use kit
(Sorin, Italy). Scintigrams were achieved in the
planar manner as well as by emission computed
tomography (ECT). In addition, 3/9 patients were
investigated by transmission CT and magnetic
resonance imaging (MRI). Three ocular melanomas
were treated by enucleation with subsequent
immunohistochemistry, 5 were treated by radiation
therapy with a 106-Ruthenium plaque.
Despite the small size of the lesions, the scinti-
graphic results were encouraging. 8/9 lesions were
visualised; this was possible by ECT only, whereas
planar scintigraphy failed to detect 4/8 ocular
melanoma. The presence of the recognised high-
molecular-weight melanoma-associated antigen
could be documented by immunohistochemistry.
The image quality confirmed that radioimmuno-
scintigraphy with ECT was able to detect lesions
smaller than 1 cm. Unspecific uptake in RES and
kidneys, however, was a limiting factor of this
antibody in other locations.ABSTRACTS OF ORAL PRESENTATIONS 541
Correlation study between tumour antigenic
expression and in vivo binding of radiolabelied
antibodies
J.Y. Douillard, P.A. Lehur, M. Kremer, G. Aillet,
J.F. Chatal & A. Bianco-Arco
Chirurgie Generale et Digestive, CHU Nord,
INSERM Unite 211 and Centre Rene Gauducheau,
Nantes, France.
In order to investigate if the amount of tumour-
specific monoclonal antibodies targeted to tumour
cells after in vivo infusion was dependent in part
upon the amount of antigenic expression at the
tumour site, a correlation study was undertaken
comparing quantitative binding of radiolabelled
antibodies to quantitative antigenic expression. 1251I
anti-CEA and 131I anti-Ca 19-9 were infused 3 days
in 6 patients and 4 days in one patient before
radical surgery for colorectal carcinoma. Three
tumour specimens were obtained during surgery
along with normal colon, fat, muscle, skin, liver
and blood sample. All specimens were evaluated for
gamma emission, expressing results as % injected
dose per gram of tissue. After counting, specimens
were assayed using avidin biotin peroxidase
complex to evaluate antigenic expression. Results
were scored from 0 to 100 taking into account both
the percentage of stained cells and the intensity of
staining.
Correlation studied for these 7 patients was
excellent for both antibodies. CEA in vivo binding
correlated to tissue antigenic expression with an r
value of 0.69 to 0.90 for each pathologist
respectively. The r value of inter-observer
correlation was 0.74. Similar good correlation was
observed for anti-Ca 19-9 antibody targeting and
Ca 19-9 expression with r values of 0.78 and 0.84
and inter-observer r of 0.97. Results of this limited
study confirm the rationale for using tumour-
specific antibodies for cancer imaging. Ability of a
given tumour to be imaged by radiolabelled
antibodies is, however, only in part dependent upon
antigenic expression, since other factors like blood
flow, vascularisation, have also to be considered for
accessibility of antibodies to tumour-associated
antigens.
Specific radioimmunotherapy with Yttrium-90
monoclonal antibody
W.T. Anderson-Berg, C.L. Ruegg & M. Strand
Department ofPharmacology and Experimental
Therapeutics, The Johns Hopkins University School
ofMedicine, Baltimore, MD 21205, USA.
The specificity, efficacy and toxicity of radio-
immunotherapy with radioiodinated monoclonal
antibody (MAb) was compared with 90Y-labelled
DTPA-derivated MAb in an animal model system.
Although tumour mass was reduced following
treatment with 131I-labelled immunoglobulin (IgG)
(ED50=50MCi), specific and control IgGs had
equal potency attributable to whole body
irradiation. In contrast, with 90Y, specific MAb
was threefold more potent than control IgG
(ED50=9 and 25 1Ci respectively). Histologically,
microscopic tumour foci were eliminated only in
animals treated with specific MAb. Further, myelo-
suppression was dose-limiting with iodine but, with
yttrium, was observed only at doses several-fold
greater than the therapeutically effective dose.
The enhanced specificity and decreased toxicity
observed with yttrium-labelled antibody can be
ascribed to both physical and biological factors.
The longer physical half-life and long range gamma
emissions of 131I increase its toxicity. Further, at
the tumour, iodinated IgG was rapidly dehalo-
genated with a Tf of 2-3h, whereas yttrium
remains stably chelated and 90Y-labelled MAb
continued to accumulate at the tumour target over
5 days. Based on these results, 90Y-labelled
antibody appears to be a promising agent for
clinical radioimmunotherapy.
Heteroantibody duplexes target tumour cells for lysis
by human cytotoxic T lymphocytes
M.A. Liu' 2, B.-A. Khaw2, H.W. Strauss2 &
N. EisenI
'Massachusetts Institute of Technology, Cambridge,
MA 02139 and 2Massachusetts General Hospital,
Boston, MA 02114, USA.
Cytotoxic T cells (Tc cells) exhibit a high degree of
specificity for their target cells. However, when
anti-idiotypic antibodies directed against the T cell
antigen-specific ap heterodimeric receptor have
been attached to diverse tumour cells, a cytotoxic T
cell clone effectively and specifically kills the
tumour cells regardless of the tumour's indigenous
surface antigens. We sought to develop a general
means for targeting tumour cells for lysis by any Tc
cell independent of the Tc cell's antigen specificity.
We used heteroantibody duplexes composed of
an antibody to T3 (which is intimately associated
with the a4 receptors on all human mature T cells)542 ABSTRACTS OF ORAL PRESENTATIONS
covalently joined to a second antibody specific for
an antigen on the intended human tumour target
cell. In the presence of the anti-T3/anti-tumour
heteroantibody duplex the tumour cells were lysed
by a clone of human T8+ Tc cells of unrelated
specificity but not by a non-cytotoxic clone of
human T4+ helper T cells. Lysis by the Tc cells
was specifically blocked by the uncoupled anti-T3
or the uncoupled anti-tumour antibodies (Liu et al.,
Proc. Natl Acad. Sci., 82, 8648, 1985). In vivo
studies with radiolabelled heteroantibodies and Tc
cells in nude mice with solid tumours are in,
progress. The usage of an anti-T3 antibody
facilitates the possible application of this technique
for immunotherapy by obviating the development
of multiple anti-idiotypic receptor antibodies.
Overall, our findings suggest that heteroantibody
duplexes containing anti-T3 antibody may be
capable of targeting selected cells, such as tumour
cells, for destruction in vivo by the body's cytotoxic
T cells.
Limitations to tumour killing using radiolabelied
antibodies
A.T.M. Vaughan, A.R. Bradwell, P. Anderson &
P.W. Dykes
Department ofImmunology, University of
Birmingham, Birmingham B15 2TJ, UK.
Using available data on the distribution of radio-
labelled antibodies in man, we have made
calculations to illustrate the conditions required for
tumour destruction following a single i.v. injection
of labelled antibody. The calculations are based on
a model containing the following variables. The
rate of uptake and loss of activity by the tumour,
the rate of elimination of activity from the whole
body and the maximum percentage uptake of
activity by the tumour. We have set as a target the
delivery of 60Gy of radiation to the tumour in one
week, following successful radiotherapy practice.
The conclusions to be drawn are clear. Using either
Iodine-131 or Yttrium-90 as an antibody label,
tumour destruction is associated with lethal whole
body irradiation. A minimum 10-fold improvement
is required in specific uptake of radioactivity into
the tumour to make therapy a practical
proposition. For all conditions studied, however,
Yttrium-90 appears the isotope of choice, due to its
lack of any gamma emission and its more energetic
beta decay. Successful therapy may result from
either increasing the specific tumour content of
radioactivity, or the extraction of radioactivity from
sites external to the tumour. The latter can be
achieved by direct immunological manipulation,
using an antibody directed against the first to clear
the blood pool, or the application of methods
utilising the particular chemistry of the isotope
label. We have investigated two chemical
approaches, Yttrium-90 may be non-specifically
removed from the body by administration of
soluble chelates. More usefully, Gold-199 bound to
antibodies is eliminated from the body as it is
cleared from the blood but, like Yttrium-90, is
retained in extravascular lbcations.
Intraperitoneal versus intravenous injection of
radiolabelled monoclonal antibodies in patients with
colorectal carcinoma
G. Paganelli, P. Riva, G. Sarti, V. Tison,
G. Cacciaguerra, G. Fiorentini, G. Moscatelli,
S. Benini & M. Agostini
Istituto Oncologico Romagnolo, 47023 Cesena, Italy.
The anti-CEA MoAb (clone F023C5-Sorin
Biomedica) employed for this study belongs to the
IgG1 class and is directed against the CEA peptide
chain. It does not react significantly with cross-
reacting antigen (NCA) and with normal colon
mucosa extracts.
Sixty patients with colorectal carcinoma were
injected i.v. with 2-3mCi of 131I-labelled F(ab')2
fragments corresponding to 300-600pg of proteins,
obtaining positive results in the 80% of
documented lesions. No positive results were
obtained both in vivo and in vitro when we used a
negative control antibody raised against the HMW-
MAA, melanoma antigen.
However, the major drawback was the low
sensitivity in liver metastases (59%) and the poor
tumour to background ratio achievable. Twenty of
these patients were injected intraperitoneally with
improved results in the detection of liver metastases
(9/11 vs. 5/11), abdomen recurrences (17/17 vs.
14/17) and lymphatic metastases (9/9 vs. 7/9).
Tumour to background ratio was also increased in
the cases mentioned above: 2.3-16.2 (mean 4.7)
after i.p. vs. 1.2-3.5 (mean 2.1) after i.v. (P<0.001).
Subtraction technique was not needed in detecting
liver metastases, even if 1311 label was used. This
was due to the low non-specific uptake in the
normal organ. We injected simultaneously, both i.v.
and i.p., the same antibody labelled with two
different isotopes in 4 patients bearing primary
colon cancer. Tumours were removed and counted
in a multichannel system. In these cases, theABSTRACTS OF ORAL PRESENTATIONS 543
antibody concentration as well as the tumour/BK
ratio were not increased by the i.p. route of
injection if the neoplastic cells did not cross the
peritoneal wall.
Diagnostic contribution of 1-131 HMFG2 in
malignant pleural and peritoneal effusions
J. Malamitsi, D. Skarlos, D. Pektasidis,
G. Aravantinos, P. Papakostas, A. Varvarigou,
J. Taylor-Papadimitriou, A.A. Epenetos &
K. Koutoulidis
Nuclear Medicine and Ist Internal Medical
Departments, NIMTS, Athens, Greece and Imperial
Cancer Research Fund, London WC2, UK.
The aim of this study was to image pleural and
peritoneal metastases of breast and ovarian
carcinomas using 131I HMFG2 monoclonal
antibody. Fourteen patients were examined, 7 with
pleural metastases from breast carcinoma and 7
with peritoneal and pelvic metastases from ovarian
carcinoma. After confirming the positive reaction of
HMFG2 with the breast and ovarian cancer cells of
the patients under study by the indirect immuno-
peroxidase staining method, radiolabelling of
HMFG, with 131I followed (iodogen or N-br-
succinimide method). After drainage of the serous
effusion, 500pCi of 1311 HMFG2 was administered
intrapleurally or intraperitoneally respectively.
Following that, the patients were scanned at 0, 2,
24, 48, 72 and 96h. Radioactivity was counted in
blood and urine specimens over 96h and total
excreted radioactivity in urine was calculated.
The selective localisation of radiolabelled
HMFG2 on pleural and peritoneal metastases was
proven over 96h, whilst radioactive concentrations
in urine and blood as well as total excreted radio-
activity in urine were negligible.
We conclude that by intrapleural and intra-
peritoneal administration of radiolabelled HMFG2
in patients with breast and ovarian cancer
respectively, a very satisfactory selective imaging of
metastases, not easily detectable by other means, is
achieved.
Abstracts of poster exhibits
Serological monitoring of breast cancer by a low pH
ELISA method
B. Dhokial , N. Courtenay-Luck' 2,
D. Pectasides', J. Taylor-Papadimitriou2, C. Self ,
N.A. Habib', M. Hershman', C.B. Wood',
A.J. Munro' & A.A. Epenetos'
'Royal Postgraduate Medical School, London W12
and 2Imperial Cancer Research Fund, London WC2,
UK.
A new, simple and sensitive low pH ELISA method
has been developed to measure serum levels of
tumour associated antigens detectable by
monoclonal antibodies HMFG1 and HMFG2. We
examined sera from healthy controls and patients
with noeplastic and non-neoplastic conditions of
breast. The majority of patients with metastatic
breast cancer had elevated serum antigens (69%
HMFG1, 72% HMFG2) compared to healthy
controls (6.3% HMFG1, 3.0% HMFG2) or
patients with benign breast disease (17% HMFG1,
4% HMFG2).
This new method promises to be of value in the
assessment ofpatients with breast cancer.
Use of monoclonal antibodies to detect circulating
epithelial membrane antigens in breast cancer
patients
J.A. Kantor, W.F. Feller, J. Hilkens & J. Hilgers
Department ofSurgery, Georgetown University,
Washington, DC, USA and Netherlands Cancer
Institute, Amsterdam, The Netherlands.
We have used two murine monoclonal antibodies,
115D8 and 67D11, derived from antigens present
on human milk fat globule membranes to detect
circulating antigens in human plasma. Plasma
samples from 61 women with breast cancer and 164
healthy controls were studied with these two murine
monoclonal antibodies and a low pH enzyme linked
immunoabsorbent assay (ELISA). 92% (56/61) of
all women with breast cancer had elevated levels of
monoclonal antibody defined antigen in their
plasma as compared to 6% (10/164) of healthy
controls. All women (6/6) with benign proliferative
breast disease had elevated levels of circulating
antibody defined antigens. We conclude that
monoclonal antibodies reactive to epithelial cell
membrane antigens can detect elevated levels of
these antigens in patients with breast cancer and
benign proliferative breast disease.544 ABSTRACTS OF ORAL PRESENTATIONS
Detection of the MAM-6 antigen in sera and urine
from breast cancer patients
D.E.A. Zanin, P.F. Bruning & J. Hilkens
Department of Tumour Biology, The Netherlands
Cancer Institute, Plesmanlaan 121, 1066 CX
Amsterdam, The Netherlands.
MAM-6 is a glandular epithelium associated
antigen reactive with monoclonal antibody 115D8.
The antigen is highly glycosylated and has an
apparent molecular weight over 400kD. MAM-6 is
present on several carcinomas, but very high
expression has been observed on breast carcinomas.
Increased MAM-6 levels were found in serum of
80% of the patients with advanced breast and
ovarian carcinoma.
TCA precipitable material immunoreactive with
115D8 was present at low levels in the urine of
apparently healthy individuals (n= 18) and
increased levels were observed in urine of breast
carcinoma patients (n=35).
We measured the urinary excretion of the renal
tubular enzymes alanine-aminopeptidase (brush-
border enzyme) and N-acetyl-B-glucosaminidase
(lysozomal enzyme). These enzymes were not
correlated with the excretion of MAM-6 like
material, suggesting that the latter was not of renal
origin. The creatinine clearance rate was normal in
all the healthy volunteers and most of the patients,
and not correlated with the clearance rate of
MAM-6. Normal individuals had low serum levels
and high MAM-6 clearance rates and in patients
serum levels were inversely related to the MAM-6
clearance rate. Further studies to investigate the
nature of the 115D8 reactive material and the
mechanism of its excretion in urine of healthy and
advanced breast cancer patients are in progress.
The clinical significance of pre-operative CA125 in
ovarian cancer
D.J. Cruickshank
Department ofObstetrics and Gynaecology,
University ofAberdeen, Scotland, UK.
There is now an extensive literature confirming that
CA125 is the most clinically useful marker in
epithelial ovarian cancer with a reported sensitivity
of 82% and 93% concordance with clinical disease
status. The published literature to date, however,
deals almost exclusively with post-operative sera
from patients with perhaps poorly quantified
persistent or recurrent disease. The aim of this
study was to evaluate the significance of pre-
operative serum levels.
Pre-operative serum CA125 estimations were
performed in 41 patients who subsequently had
epithelial ovarian cancer histologically confirmed.
Both the frequency of positively (CA125> Uml-P)
and absolute CA125 level correlated with FIGO
stage (tumour load). All histological types released
CA125 into the serum although serous and
undifferentiated tumours secreted quantitatively
more antigen. There was no correlation between
CA125 level and histological grade suggesting
CA125 is not a differentiation antigen. Similarly,
pre-operative CA125 did not predict outcome as
defined by clinical status (responder or non-
responder) at last presentation.
In this series the sensitivity of CA125 was 73%
(30/41). FIGO Iaii was the earliest stage disease
expressing significant pre-operative levels of CA125
(2/5) with 0/6 FIGO Iai cases positive. This may be
because the tumour capsule must be breached
(FIGO Iaii) to release the antigen or the threshold
of detection of CA125 is associated with a tumour
volume greater than that found in Iai disease.
The role of c-myc oncogene expression in the
development of gastric cancer
F. Macdonald, W.H. Allum, H. Stokes, B. Russell
& J.W.L. Fielding
Surgical Immunology Unit, Queen Elizabeth
Hospital, Birmingham, UK.
Oncogenes have been associated with a variety of
different cancers including those of the gastro-
intestinal tract. We have used a monoclonal
antibody to the p62 protein product of the myc
oncogene in an immunoperoxidase study of normal
stomach, premalignant and inflammatory lesions of
the stomach as well as gastric cancer and
autologous lymph node metastasis to determine
whether this oncogene plays any role in the
development of gastric malignancies.
Staining occurred in either the parietal cells
and/or the surface epithelium depending on the
pathology. Parietal cells were positive in all 16
normal stomachs tested. Three showed weak
staining of less than 5% of the surface epithelium.
Biopsies from chronic superficial gastritis were
weaker in comparison, with only 7/19 positive,
again in the parietal cells. Only one biopsy showedABSTRACTS OF ORAL PRESENTATIONS 545
intense surface staining. 9/20 biopsies from
intestinal metaplasia were positive in the parietal
cells and 9 also showed surface staining. Dysplastic
lesions exhibited the most intense staining. Parietal
cells in all 20 biopsies were strongly positive. Over
50% of surface cells were positive in 8/20
specimens, between 25 and 50% of cells were
positive in a further 4. The remaining 8 were either
negative or weakly reactive and these were classified
primarily as mild dysplasias. A wide range of
reactivity was seen in the cancers and their lymph
node metastases although the intensity of staining
was never as strong as in the dysplastic lesions.
These results suggest that increased expression of
the myc oncogene is an early event in the
development of gastric cancer.
Reactivity of monoclonal antibodies with human
gliomas
D. Stavrou, K. Staemmler, E. Keiditsch,
F. Schmidberger, I. Funke & P. Mehraein
Institute ofPathology and Department of
Neurosurgery, Clinicum Bogenhausen; Institute of
Immunology and Institute ofNeuropathology,
University ofMunich, FRG.
BALB/c mice were immunised with cells from a
malignant astrocytoma. Hybridoma cells were
tested for antibody production against different cell
monolayers and tissue sections. The binding of
Mabs MUG-I to MUC-15 is shown in the table:
Murine monoclonal antibodies
Human tissue MUC-J MUC-2 MUC-3
Normal brain (loccip., m.,
70 yrs) + + +
Embryonic cells
(brain anlage,
9 wks) + + +
Blood monocytes,
colon carcinoma,
breast carcinoma
Melanoma,
astrocytoma,
glioblastoma + + +
Murine monoclonal antibodies
MUC-7
to
Human tissue MUC-4 MUC-S MUC-IS
Normal brain (loccip., m.,
70 yrs) + +
Embryonic cells
(brain anlage,
9 wks) + + +
Blood monocytes,
colon carcinoma,
breast carcinoma - - -
Melanoma,
astrocytoma,
glioblastoma + + +
This shows that the established hybridomas
produce antibodies which bind to different cell
types enabling discrimination between normal and
neoplastic brain cells. Variable antigenic profiles
among glioma cell populations could be
demonstrated. Antigens recognised by the MUC-7
to MUC-15 antibodies persist after fixation with
acetone, glutaraldehyde and Bouin solutions and
are likely to be differentiation antigen(s).
Immunophenotype of cytomorphologicaily defined
acute lymphoid leukaemias
D. Batinic & M. Boranic
Ruder Boskovic Institute, Zagreb, Yugoslavia.
The diagnostic value of a selected panel of
monoclonal antibodies specific for lymphoid cells
was assessed in 39 patients (23 children and 16
adults) with newly diagnosed acute leukaemia,
initially assigned as acute lymphoid leukaemia
(ALL) by cytomorphological criteria. There were an
additional 6 children with ALL in relapse. Samples
(peripheral blood and bone marrow) containing
more than 30% blasts were accepted for the study.
Using Coulter Clone monoclonal antibodies Ti1,
T4, T8, Bi, 12 (anti-Ia) and J5 (CALLA) in indirect
immunofluorescent test and FITC-conjugated
rabbit anti-human Ig antiserum (Inep-Torlak) in
direct immunofluorescent test, 4 major blast
phenotypes could be distinguished: T (Til, T8+/-,
T4+/-), B (Ia, Bi, mlg), pre-B 'common' (Ia,
CALLA, Bi+ or BI-), and 'null' (Ia' or la-). In
view of the relatively high proportion of negatively-
defined 'null' type leukaemias (11 of 45, especially
in children - 5/23 newly diagnosed and 2/6 in546 ABSTRACTS OF ORAL PRESENTATIONS
relapse), some of the antibodies used for the first-
line screening of acute leukaemias should be
replaced by those determining more precisely the
cellular origin of 'null' leukaemias, e.g. by pan-
antibodies (for T-, B- and myeloid cells) that have
become commercially available.
CA-50 radioimmunoassay inhibition test for diagnosis
of prostatic carcinomas
M.J. Hershman, N.A. Habib, M.A. Ferro,
C.J. Roberts, K.M. Campion, F. Haberland,
R.C.N. Williamson & C.B. Wood
Departments ofSurgery, Royal Postgraduate
Medical School, London and Bristol Royal
Infirmary, Bristol, UK.
Site and accessibility ofAUA, antigen: Its relevance
to antibody-guided irradiation
W.J. Mooi, T. Krausz, S. Kirkland, A. Cross &
A.A. Epenetos
Departments ofHistopathology and Clinical
Oncology, Royal Postgraduate Medical School,
London W12, UK.
The success of antibody-guided irradiation of
tumours is not as constant and complete as one
might anticipate on the basis of immunostaining
results of tumour material. An explanation may be
that antigens are present on tumour cells but may
be inaccessible due to their location in the in vivo
situation.
To investigate this, we assessed the reactivity of a
colon carcinoma cell line, HRA-19, before and after
alcohol fixation, to the monoclonal antibody
AUA1, recognising an antigen present on the
basolateral surface of neoplastic and non-neoplastic
epithelial cells. The HRA-19 cells were grown on
glass coverslips, forming compact colonies. After
incubation of live cells with AUA1, the cells were
alcohol fixed for immunoperoxidase staining. The
results were compared to the immunoreactivity
when the cells were alcohol-fixed prior to
incubation with AUA1.
The live incubation resulted in staining of a rim
of cells at the periphery but not in the centres of
the colony. Alcohol fixation prior to incubation
with AUA1 resulted in strong staining of cell
membranes also in the colony centres. This latter
pattern was also seen when AUA1 was applied
twice: on live cells and again after alcohol fixation.
This excluded the possibility of antibody-induced
antigenic modulation. Incubation of live cells with
EDTA (which induces dissociation of the live cells)
also resulted in strong staining ofcolony centres.
We conclude that accessibility of antigen is an
important factor in antibody binding to live cells.
In view of these findings, we suggest that screening
of immunoreactivity of cancer cells for antibody-
guided irradiation should be carried out on live
tumour material.
Cancer cells may secrete or express on their cell
surfaces 'foetal components' not normally present
in adult cells and may be detected in serum as
'oncofoetal antigens'. Recently, a new antigen, CA-
50, has been isolated as a monosialoganglioside
which is shed into the serum and can be detected
using a radio-immunoassay technique. CA-50 has
been shown to be raised in between 50-70% of
patients with colorectal, pancreatic and liver cancer.
This study assessed the significance of CA-50 in
benign and malignant lung disease. Based on a
normal population study a level of 17Uml-1 was
used as a cut-off level between benign and
malignant diseases.
The serum CA-50 level was measured in 60
normal individuals and 61 with benign prostatic
hypertrophy. All normal subjects and 59 of 61
(97%) patients with BPH had levels below
17Uml-1 with mean values of 8.7+5.3 and
5.0+4.3 respectively. Twenty-nine of 69 (43%)
patients with prostatic cancer had raised serum
levels (mean of positive values, 32.4+ 16.2). Thirty-
four patients had metastases of which 24 had
positive values (71%), significantly different from 5
positive values in 34 patients without metastases
(15%) (P<0.001). Zero of 8 well differentiated
tumours were positive compared with 11 of 33
moderate differential tumours (33%) and 18 of 27
poorly differentiated tumours (66%).
These data suggest that CA-50 levels correlate
with stage and grade of prostatic cancer for which
it has a high specificity and may therefore have a
role as a tumour marker in this condition.
The expression of sis gene in the colonic adenoma-
carcinoma sequence
N.A. Habib, G.U.A. Igboaka, M.J. Hershman,
R.C.N. Williamson, C.B. Wood & J.W.B. Bradfield
Departments ofPathology and Surgery, Bristol
Royal Infirmary, Bristol and Department ofSurgery,
Royal Postgraduate Medical School, London, UK.
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the sis gene product (p20) and platelet-derived
growth factor (PDGF) provide a link between the
transforming properties of oncogenes and the
mitogenic action of growth factors.
The purpose of this study was to investigate the
expression and distribution of the human c-sis
oncogene product, p20, by peroxidase-anti-
peroxidase technique using monoclonal antibodies
to p20, in normal and neoplastic colonic
epithelium. We have examined 20 normals, 85
tubulovillous adenomas (24 with mild dysplasia, 14
moderate dysplasia, 31 severe dysplasia and 16 with
invasive cancer). It was found that there was no
difference in staining intensity or distribution in the
superficial parts of the mucosa in both normal and
neoplastic tissue. By contrast, p20 was absent in the
deep parts of the glandular epithelium in normal
mucosa and it was present with varying degrees in
neoplastic tissue. There was a significant increase in
the p20 staining of the deep parts of the mucosa as
the tissue progressed from mild (12%) through
severe dysplasia (23%), reaching 88% incidence in
invasive cancer.
CA-50 radioimmunoassay inhibition test in liver,
pancreatic and colonic carcinomas
M.J. Hershman, N.A. Habib, C.J. Roberts,
K.M. Campion, R.I. Swift, V. Kallmeyer,
R.C.N. Williamson & C.B. Wood
Departments ofSurgery, Royal Postgraduate
Medical School, London and Bristol Royal
Infirmary, Bristol, UK.
Recently, a new antigen, CA-50, has been isolated
as a monosialoganglioside. This antigen is shed into
the serum and can be detected using radioimmuno-
assay technique. The antigen level of 17Uml- I
based on normal population study was used as a
cut-off level between benign and malignant diseases.
The clinical application of this test in colorectal
diseases has shown that all normal subjects (n=50)
and control patients with inflammatory diseases
(n=20) had levels below 17 Uml-1. This test was
positive in 40 of 77 (51%) patients with colorectal
carcinomas. In the field of pancreatic diseases, 8 of
9 patients with pancreatitis were negative. Twenty-
four of 26 (92%) patients with pancreatic
carcinoma had CA-50 levels above 17 Uml-1.
Lastly, in liver diseases, we found that 25 of 28
(89%) patients with benign liver diseases had a CA-
50 level below 17Uml-1, while 2 patients with
sclerosing cholangitis and 55 of 88 (63%) of
patients with liver tumours were positive.
The CA-50 test seems to be a useful non-specific
tumour marker.
CA-50 radioimmunoassay inhibition test for diagnosis
of lung carcinomas
N.A. Habib, M.J. Hershman, C.J. Roberts,
R. Stein, D.T. Reilly, R.I. Swift,
R.C.N. Williamson & C.B. Wood
Departments ofSurgery, Bristol Royal Infirmary
and Royal Postgraduate Medical School, London,
UK.
This study assessed the significance of CA-50 in
benign and malignant lung disease. based on a
normal population study, a level of 17Uml-I was
used as a cut-off level between benign and
malignant diseases. The serum CA-50 level was
measured in 50 normal individuals and 28 with
inflammatory lung conditions, including 10 TB, 3
sarcoid, 6 alveolitis, 9 acute bronchitis+pneumonia.
All normal subjects and 27 of 28 (96%) patients
with benign lung conditions had levels below
17Uml-I with a mean value of 10.1+4.9. Twenty-
one of 55 (38%) patients with lung cancer had
raised serum levels (mean 32.3±16.5). Six of 13
(46%) squamous tumours were positive, compared
to 14 of 24 (58%) oat cell tumours, 1 out of 4
adenocarcinomas, none of 12 large cell tumours,
and none of 2 lymphomas.
These data suggest CA-50 may be a useful
tumour marker for lung cancer, particularly if used
in conjunction with other markers.
The localisation of the human c-myc gene product
(p62) in normal and neoplastic human colonic mucosa
G.U.A. Igboaka, N.A. Habib, M.J. Hershman,
R.C.N. Williamson, C.B. Wood, J.W.B. Bradfield,
G. Evan & K. Sikora
Departments ofPathology and Surgery, Bristol
Royal Infirmary, Bristol and Departments of Clinical
Oncology and Surgery, Royal Postgraduate Medical
School, London, UK.
Cellular oncogenes are concerned with the
regulation of normal cell growth and differenti-
ation. Over-expression of these genes may be
associated with some malignant diseases. The
purpose of this study was to examine the expression548 ABSTRACTS OF ORAL PRESENTATIONS
and distribution of the human c-myc gene product,
p62, by peroxidase-antiperoxidase technique using
monoclonal antibodies to p62, myc-1 6E10 in
normal and neoplastic colonic epithelium.
We examined 20 normal, 75 tubulovillous
adenomas (18 with mild dysplasia, 16 moderate
dysplasia, 31 severe dysplasia and 10 with invasive
cancer).
The distribution and the intensity of staining with
myc-1 6E10 showed a pattern. The intracytoplasmic
p62 increased significantly as the tissue progressed
from mild through severe dysplasia to invasive
cancer. With increasing dysplasia, there was an
increase in the oncogene expression at the lower
parts ofglandular epithelium.
The expression of ras-oncogene in the normal and
neoplastic colonic mucosa
G.U.A. Igboaka, N.A. Habib, J.W.B. Bradfield,
M.J. Hershman, R.C.N. Williamson & C.B. Wood
Department ofSurgery, Royal Postgraduate Medical
School, London and Departments ofPathology and
Surgery, Bristol Royal Infirmary, Bristol, UK.
Oncogene over-expression is associated with
malignant transformation of normal cells.
Activation of c-ras oncogene, which is situated on
chromosome 12 in humans, has been demonstrated
in colonic carcinomas. The purpose of this study
was to examine the expression and distribution of
the normal form of ras-oncogene product (p21) by
peroxidase-antiperoxidase technique using mono-
clonal antibodies to p21 in normal and neoplastic
colonic epithelium.
We have examined 20 normal, 21 metaplastic
polyps, 75 tubulovillous adenomas (6 with mild
dysplasia, 27 moderate dysplasia, 32 severe
dysplasia and 10 with invasive cancer). It was
found that the p21 expression significantly
increased as the tissue progressed from normal
through mild and severe dysplasia and finally
invasive cancer. In metaplastic polyps there was a
decrease in p21 expression compared to normal. By
contrast, in neoplastic tissue, both the intensity and
distribution of p21 showed a pattern in that with
increasing dysplasia there was an increase in
expression of p21 in the lower parts of the
glandular epithelium.
Immunohistochemical localisation of tumour markers
in a human cell line
T.W. Briers, E.J. Nouwen, S. Dauwe,
P. Stroobants, P.G. Hendrix, D.E. Pollet &
M.E. De Broe
Department ofNephrology-Hypertension, University
Hospital, Antwerp, Belgium.
The cell line DOooo-s originated from the ascites of
a patient with a mucinous cystadenocarcinoma of
the ovary (January, 1985). The cells were cultured
as a suspension in RPMI-1640 supplemented with
2% FCS or in Dulbecco's MEM supplemented with
5% FCS. They were vermiform and appeared as
clusters of 10 to 30 cells surrounded by a glyco-
protein layer.
Prominent nuclei, numerous vacuoles, lipid
droplets, and bizarre mitochondria were ultra-
structural characteristics of these cells. HPLAP,
CA125, HMFG (1 & 2), CA19-9 and CEA were
localised on paraffin sections using monoclonal
antibodies (respectively H17E2, 17E3, E6 and
H327; OC125; HMFG1 and 2; the Hybritech
antibody). All cells were positive for CA125 and
HMFG2. The stain was normally found on the
plasma membrane and some staining was present in
the cytoplasm. For HMFG1, small groups of cells
were positive. Only 17E3 and E6 could visualise
HPLAP in single or small groups of cells. Histo-
chemical AP activity was completely inhibited by
L-phenylalanine and was almost not influenced by
L-bromotetramisole. These results indicate that in
DOooo-s AP is present as HPLAP. The cells were
not positive for CA19-9. Light microscopic analysis
was confirmed by electron microscopy of immuno-
histochemically stained cells. In xenografts induced
in athymic nude mice the same immunohisto-
chemical pattern could be demonstrated.
Construction and characterisation of a murine/human
chimeric MAb using recombinant DNA techniques
G.P. Moore, S. Sahagan, H.D. Dorai,
J. Saltzgaber-Muller, G. Davis & F. Tonneguzzo
E.L du Pont de Nemours, Co., Inc., No. Billerica,
MA, USA.
Chimeric immunoglobulin genes were constructed
by fusing murine variable region exons to human
constant region exons. The ultimate goal was to
produce an antibody capable of escapingABSTRACTS OF ORAL PRESENTATIONS 549
surveillance by the human immune system while
retaining the tumour specificity of a murine mono-
clonal. The murine variable regions were isolated
from the functionally expressed kappa and gamma
1 immunoglobulin genes of the murine hybridoma
cell line B6.2, whose secreted monoclonal antibody
reacts with a surface antigen from human breast,
lung and colon carcinomas. The kappa and gamma
1 chain fusion genes were co-introduced into non-
antibody producing murine myeloma cells by
electroporation. Transfectants which produce
murine/human chimeric antibody were obtained at
high frequency as indicated by immunoblots probed
with an antisera specific for human immuno-
globulin. ELISA analysis demonstrated that this
chimeric antibody is secreted from the myeloma
cells and retains the ability to bind selectively to
human tumour cells. The ability of chimeric
antibody to recognise human tumour-associated
antigen makes feasible a novel approach to cancer
immunotherapy.
All subsequent studies occurred 24h post-
preparation. A live cell radioimmunoassay of
H17E2-DTPA-9°Y on HEP2 cells (PLAP +ve) and
MCF7 cells (PLAP -ve) showed 51% and 4%
binding respectively. HPLC analysis revealed 97%
of the 90Y on monomeric IgG, the remaining 3%
being free isotope.
These preliminary results are promising since 24h
post-preparation >50% antigen binding is retained
with no evidence of radiolysis or aggregation.
Extended analysis of site-specific antibody labelling
methodology: 111-Indium radioimmunoimaging in
nude mice with MAbs against renal cell, colon and
breast carcinoma
V.L. Alvarez, A.D. Lopes, C. Lee, J.D. Rodwell &
T.J. McKearn
Cytogen Corporation, Princeton, NJ 08540, USA.
Yttrium-90 radiolabelling of the monoclonal antibody
H17E2. Preliminary results
D. Snook & A.A. Epenetos
Royal Postgraduate Medical School, London W12
and Imperial Cancer Research Fund, London WC2,
UK.
Placental alkaline phosphatase (PLAP), the antigen
for H17E2, is expressed in a variety of neoplasms.
Indium-Ill (1I IIn) labelled HI7E2 has been used
successfully for radioimmunodetection in patients.
Yttrium-90 (90Y) is a potentially useful isotope for
radioimmunotherapy because it is a pure fl-emitter
(E,Bmax 2.3 MeV, t' 64h), can be generator
produced and bound to antibodies by the same
method as "'1In (Hnatowich et al., J. Nucl. Med.,
26, 503, 1985).
H17E2 was conjugated to diethylenetriamine-
pentacetic acid (DTPA) using an anhydride to
antibody molar ratio of 42:1. An average of
1.6 DTPA molecules per H17E2 molecule were
bound.
90Y was produced at AERE Harwell and
contained <1pCi Strontium-90mCi1 90Y. 90Y in
0.04 M HC1 was mixed with 3.8% (w/v) sodium
citrate, the H17E2-DTPA conjugate added and
incubated for 2h at 22°C, pH 7.0. Purification by
Sephadex G50 column gave a labelling efficiency of
61%. A specific activity of -0.5pCi 90ypg-
H17E2 was achieved.
Site-specifically modified monoclonal antibodies
have been shown to give excellent 111-Indium
radioimmunoimaging in a BN-rat lymphoma xeno-
graft system (Rodwell et al., Proc. Natl Acad. Sci.,
in press). We report here several other systems
using human tumour xenografts in nude mice and
monoclonal antibodies characterised by other
groups. These are: a renal cell carcinoma cell line,
7860 and two antibodies, A6H (IgGI; Moon et al.,
J. Urol., 130, 584, 1983) and S4 (IgG2a; Cordon-
Cardo et al., J. Hist. Cyt., 32, 1035, 1984), a colon
carcinoma using the cell lines HT29 and SW403
and the antibody HT29.15 (IgGI; Ueda et al., Proc.
Nat! Acad. Sci., 78, 5122, 1981); and the
breast/colon tumour-reactive antibodies B72.3 and
B6.2 (both IgGI; Schlom et al., Adv. Cancer Res.,
43, 143, 1985) tested on xenografts of the colon cell
line LS174T and breast cell lines MS-1, BT20 and
ZR75-1. Each antibody/tumour system gave
excellent imaging results, substantiating the benefit
of site-specific modification. Immunoreactivity was
largely retained, with values ranging from 98% of
the control for A6H and S4 to better than 90% for
B72.3. Among the differences noted were: one, rate
of localisation. Both anti-renal cell carcinoma
antibodies localised within 6h, while the B72.3
showed optimal localisation only after 72h. Other
antibodies showed intermediate localisation times.
Two, target antigen variability. HT29.15 recognised
a shed antigen on the xenograft HT29.15, but the
antigen on SW403 appeared not to be shed.
Finally, the dose of antibody that saturates each
tumour ranged from 10pg antibody g-1 tumour for
the S4/7860 system to greater than 200 gg-550 ABSTRACTS OF ORAL PRESENTATIONS
tumour for the B72.3/LS174T system. We conclude
that site-specific modification of tumour-reactive
monoclonal antibodies results in excellent imaging
and biodistribution results.
Labelling of monoclonal antibodies with a 67Ga
phenolic aminocarboxylic acid chelate (P-EDDHA)
J. Schuhmacher & S. Matzku
Institute ofNuclear Medicine, German Cancer
Research Center, Heidelberg, FRG.
Labelling of antibody with 67Ga was achieved by
coupling of the pre-formed Ga complex of
propionic acid substituted ethylenediamine-N,N'-di-
<(o-hydroxyphenyl)acetic acid> via carbodiimide to
the anti-melanoma monoclonal antibody M.2.9.4.
This was accompanied by a low degree of
oligomerization but a considerable degree of intra-
molecular cross-linking, which however, did not
impair immunoreactivity nor the half-life of labelled
antibody in vivo. Biodistribution analysis in normal
mice in comparison to the "'I-labelled antibody
showed Ga:I ratios near unity in the blood and in
all tissues devoid of degradative or excretory
potential. In tissues of the reticulo-endothelial
system and in the kidneys, Ga:I ratios up to 2.5
were reached within 4days after application. In the
antigen-positive MeWo tumour, 67Ga retention was
clearly superior, so that the tumour:organ ratios
obtained with the 67Ga-labelled antibody were
higher than those of the "'I-antibody in all organs
but the liver. It is concluded that the method of
coupling pre-established 67Ga P-EDDHA chelate to
antibody results in a functionally intact tracer
molecule, whose persistence in vivo is not
significantly impaired. The major difference to I-
labelled antibodies may consist in a prolonged
retention of Ga in tissues (cells) involved in
antibody catabolism.
Factors affecting the routine preparation of In-1ll
DTPA labelled antibodies
A.P. Richardson', P.J. Mountford', E. Heyderman2
& A.J. Coakley'
'Department ofNuclear Medicine, Kent and
Canterbury Hospital, Kent CTJ 3NG, and 2United
Medical and Dental Schools, St. Thomas's Hospital,
London SE], UK.
Radioimmunolocalisation using antibodies labelled
with In-Ill DTPA has been the subject of research
at a number of centres and consequently a range of
labelling regimes is practised. Wider use of the
technique requires the availability of more effective
antibodies and the improvement and standardisa-
tion of labelling methods.
We have examined the labelling of antibodies
with In- 111 and report a simple procedure which
can be completed to pharmaceutical standard in
less than one working day. Labelling efficiency,
antibody activity and reaction rate (see table below)
are examined.
Rate ofchelation ofIn-Hll DTPA-antibody (by TLC)
Time (h) Labelling efficiency (%)
0 5.6
0.08 42.3
0.25 70.9
0.75 85.0
2.25 89.0
6.75 87.9
23.30 88.2
Furthermore, we show that antibodies may be
conjugated with DTPA in batch (with quality
control carried out at this stage). Samples were
sterilized and stored until required. In-111 chloride
was then simply added and the efficiency of
labelling determined by TLC. By this means a
regional centre with access to antibodies could act as
a source of pharmaceutical grade DTPA-antibody
in 'kit' form. It would distribute these antibody kits
to other departments to be stored until required
when simple labelling with In-Ill is completed in
one hour to be ready for use in patient studies.
199Au, "'Ag, 143Pr-radionucides for
radioimmunotherapy in India
D.K. Hazra', S. Dass2, V. Lahiri', M. Kumari',
S. Saran' & R. Singh'
'Department ofNuclear Medicine, SN Medical
College, Agra and 2Department ofChemistry,
Dayalbagh Educational Institue, Dayalbagh, Agra,
India.
Radioimmunotherapy (RIT) requires the use of
isotopes emitting high LET radiations, alpha,
energetic beta or auger electrons. Their half-life
should permit not only radiochemical processingABSTRACTS OF ORAL PRESENTATIONS 551
but also tumour accumulation and adequate
tumour residence time; and preferably minimal
bone localisation in the event of the isotope being
deconjugated from the antibody. The daughter
products should not be undesirable.
Cyclotron-produced radionuclides are not
available in India. Out of a short list of about 15
radionuclides, 199Ag, "1 Ag, 143Pr, 122Sb and
186Re are suitable from the above viewpoints. The
radiochemistry and preparation of these radio-
nuclides in carrier-free state is described vis a' vis
their suitability for linkage to bifunctional chelates
and relevant methods are being optimised and will
be described.
Radiolabelied monoclonal antibodies against human
carcinomas: Effect of incubation in human serum on
the binding activity
M. Ripamonti, S. Canevari, S. Camagni,
D. Mezzanzanica, R. Orlandi & M.L. Colnaghi
Istituto Nazionale Tumori, Milan, Italy
Murine monoclonal antibodies (MoAbs) with
restricted reactivity for breast or ovarian
carcinomas were labelled with 125I in the
perspective of obtaining specific and stable radio-
immunopharmaceutical reagents. Three radio-
labelled MoAbs (MBrl and MOv2 of IgM class
and MOv8 of IgG class) were found to maintain
their integrity, homogeneity and binding specificity
after iodination and were further analysed for their
in vitro stability in human blood. The MoAbs were
incubated at 37'C for various lengths of time in
human or, as control, murine blood and their
binding capacity, evaluated by solid-phase RIA,
was compared with that obtained after incubation
with buffer. In human blood, serum and plasma,
but not with other components such as erythro-
cytes, leucocytes, HSA and IgG, the MoAbs
revealed a loss of binding reactivity which was
marked and constant for IgM MoAbs and only
occasional for the IgG MoAb. In murine serum the
decrease was not so evident nor so rapid. The same
change in the binding capacity was observed when
the MoAbs were labelled with 3H or 35S or when
they were incubated in the presence of protease
inhibitors. In the perspective of using IgM MoAbs
for intraperitoneal therapy we are now evaluating
the effect of ascitic fluid on their binding activity.
(Partially supported by grants from the Italian
National Research Council, Contracts no.
85.02067.44 and 85.01499.57).
In vitro removal of carcinoma cells from bone
marrow using a pool of monoclonal antibodies and
magnetic beads
G. Porro, S. Villa, S. Menard & M.I. Colnaghi
Istituto Nazionale Tumori, Milan, Italy.
Several methods involving monoclonal antibodies
have been used to remove tumour cells from bone
marrow in the perspective of autologous trans-
plantation. However, due to tumour heterogeneity
in particular, with these methods purging was
incomplete. In order to overcome this obstacle, we
selected different murine monoclonal antibodies
which had complementary antitumour reactivities
with the aim of creating a suitable pool. This pool
was capable of recognising 100% of the tested
carcinomas and 90-100% of the tumour cells
within a given tumour and, moreover, it is
unreactive with normal bone marrow cells. The
usefulness of the pool for specific detection of
metastatic cells in bone marrow suspensions was
demonstrated. Subsequently, the pool was studied
to evaluate its ability to purge bone marrow in
vitro. To this end tumour cells, stained with
bisbenzimide and treated with the pool, were
artificially mixed with normal bone marrow cells.
After incubation with antimurine Ig-linked
magnetic beads, the cell suspension was passed
through a magnetic field and the number of tumour
cells still present was then determined by the count
of bisbenzimide stained cells. This procedure
allowed the removal of 75-95% of tumour cells,
depending on the technique used. The possible
negative effect on the the bone marrow stem cells
was measured in CFU/c assays.
(Partially supported by a grant from the Italian
National Research Council, Special Project
'Oncology', Contract no. 85.02103.44.)
In vivo fate and anti-tumour activity of ricin A-chain
and deglycosylated-ricin A-chain immunotoxins
D.C. Blakey, G.J. Watson, P.P. Knowles &
P.E. Thorpe
Imperial Cancer Research Fund, PO Box 123,
Lincoln's Inn Fields, London WC2, UK.
The ability of ricin A-chain immunotoxins to
prolong the survival time of tumour bearing mice
has been less dramatic than might have been
expected from in vitro studies. This may reflect their
rapid clearance from the blood possibly by hepatic552 ABSTRACTS OF ORAL PRESENTATIONS
reticuloendothelial cells which possess receptors
that can bind the mannose terminal oligo-
saccharides present on ricin A-chain. The effect of
chemical deglycosylation of ricin A-chain on the in
vivo fate and anti-tumour activity of monoclonal
anti-Thyl.1 antibody-ricin A-chain immunotoxins
has been investigated. The ricin A-chain immuno-
toxin was rapidly removed from the bloodstream of
mice, only 10% of the injected immunotoxin
remaining in the bloodstream 3 h after i.v.
administration. The major site of clearance was the
liver, -30% of the injected dose localising in this
tissue within 10min. The deglycosylated ricin A-
chain immunotoxin was cleared less rapidly, 10%
of the injected dose still remaining in the blood-
stream after 16h and liver uptake was greatly
diminished. Both immunotoxins were equally
effective at inhibiting protein synthesis in vitro, in
AKR-A cells which express Thyl.1 antigen. In
contrast, the deglycosylated ricin A-chain immuno-
toxin was significantly more effective than the
native ricin A-chain immunotoxin at prolonging the
survival time of mice injected with AKR-A cells
intraperitoneally. It is concluded that recognition of
the terminal oligosaccharides present on ricin A-
chain does reduce the anti-tumour activity of ricin
A-chain immunotoxins in vivo and that this can be
overcome by chemical deglycosylation of the ricin
A-chain.
Identification of immunoreactive monoclonal antibody
fragments for unproved immunoscintigraphy
S.J. Mather & H. Durbin
Imperial Cancer Research Fund, PO Box 123,
Lincoln's Inn Fields, London WC2, UK.
Recent results obtained in animal models and
confirmed in patient studies have indicated that
antibody fragments possess advantages over the
whole immunoglobulin for in vivo localisation
studies.
Proteolytic digestion of monoclonal antibodies
does not always, however, follow classical textbook
dogma. Different antibody isotypes respond to
digestion in different ways and even within a class
of antibody such as the common IgGl, large differ-
ences can be observed.
This report describes a method whereby immuno-
reactive products of antibody digestion can be
easily identified. This permits parameters such as
the choice of enzyme and digestion conditions to be
optimised with a minimum of effort.
Following a suggested digestion protocol, the
products of digestion are separated by SDS-
polyacrylamide gel electrophoresis. The gel may be
stained to indicate the number of protein fragments
and their molecular weights. The proteins from an
unstained gel are now transferred to nitrocellulose
paper by 'Western blotting' and the nitrocellulose is
incubated with an antigen probe relevant to the
antibodies under investigation in order that immune
fragments may be identified.
In addition to simplifying the digestion of an
antibody of particular interest and promise, this
procedure permits a series of closely related
antibodies to be screened for the ability to produce
good yields of immunoreactive fragments.
Human recombinant y-interferon enhances in vivo
expression of HLA-DR antigen
G. Rowlinson1, F. Balkwill2, D. Snook2'3.
G. Hooker3 & A.A. Epenetos2 3
1MRC Cyclotron Unit, Hammersmith Hospital,
21mperial Cancer Research Fund, Lincoln's Inn
Fields, London WC2 and 3Royal Postgraduate
Medical School and Hammersmith Hospital, London
W12, UK.
Athymic (nude) mice bearing subcutaneous human
breast tumours were treated systemically with
recombinant human interferon-y, rHulFN-y. These
tumours were phenotypically negative for HLA-DR
prior to therapy, but after 4 days of treatment 80%
of the cells expressed this antigen in vivo, as
assessed by immunoperoxidase staining.
A radioiodine-labelled murine monoclonal
antibody TAL-IB5 against HLA-DR specifically
localised to the tumours in rHulFN-y-treated mice
but not in control mice. Tumour to normal tissue
ratios greater than 10 were obtained in treated
mice. An isotype identical murine monoclonal
antibody that did not react with this tumour did
not show any specific localisation in control or
rHulFN-y-treated mice.
These results demonstrate that specific localisa-
tion to tumours of radiolabelled monoclonal
antibodies to HLA-DR can be facilitated by
systemic therapy with lFN-y.ABSTRACTS OF ORAL PRESENTATIONS 553
Antibody guided localisation of intraperitoneal
tumours following i.p. or i.v. antibody administration
G. Rowlinson', D. Snook2' , A. Busza' & A.A.
EpenetOS2,3
'MRC Cyclotron Unit, Hammersmith Hospital,
2Imperial Cancer Research Fund, Lincoln's Inn
Fields, London WC2 and 3Royal Postgraduate
Medical School, Hammersmith Hospital, London
W12, UK.
Intraperitoneal delivery of monoclonal antibodies
may prove beneficial in the diagnosis and therapy
ofmalignancies involving the peritoneum.
I.p. tumours of the colon carcinoma cell line
LoVo were established in athymic (nude) mice by
i.p. inoculation of a single cell suspension. Two
preparations of monoclonal antibody AUA1, radio-
labelled with 125-Iodine or 131-Iodine, were
injected i.p. and i.v. into the same animals.
Localisation was assessed by dissection and
counting the activity in tumour and normal organs.
Tumour/tissue ratios 1 h after i.p. injection were
approximately 50 times higher than after i.v.
administration. This i.p./i.v. advantage fell to -4
by 8h, and to just greater than 1 by 24h. When an
irrelevant antibody raised against a different
tumour was injected intraperitoneally, there was
slight tumour uptake within the first 4h, but this
fell rapidly to normal organ levels by 12h. In
contrast, the specific antibody remained specifically
bound to the tumour for several days.
Xenograft localisation of a monoclonal antibody
reacting with colorectal cancer
C.Y. Yiul, L.A. Baker1, K. Roberts2,
J.H. Westwood3, R.C. Coombes2 3 & C.G. Clark'
'Department ofSurgery, University College, London,
2Royal Marsden Hospital, Surrey and 3Ludwig
Institutefor Cancer Research, London Branch, UK.
A mouse monoclonal antibody 77.1 of the IgG2a
subclass showed positive immunocytochemical
staining of colorectal cancer sections (Yiu et al,
Anticancer Res., 5, 608, 1985) and with a renal
carcinoma xenograft XKI. A xenograft localisation
study was undertaken to assess its potential for
clinical radioimmunodetection.
48.2, a mouse monoclonal antibody, which was
non-reactive with XKI, was used as control.
Antibodies were labelled with 125-Iodine by the
iodogen method. XKI was implanted subcutane-
ously into flanks of nude mice. Each mouse was
injected i.p. with 1-2MBq (500-10OOng) of labelled
antibody and sacrificed 24, 48 and 72h later (4
mice/time point/monoclonal).
The tumour to blood ratios (T:B) for 77.1 at 24,
48 and 72h were mean +s.e. 1.37+0.08,
1.88+0.45, 2.36+0.32; for 48.2 0.40+0.08,
0.49+0.06, 0.53 +0.005. The localisation indices,
i.e. T:B 77.1/T:B 48.2 were 3.42, 3.83 and 4.34.
The results showed that specific localisation of
77.1 was achieved with the xenograft and suggested
its suitability for radioimmunodetection of colo-
rectal cancer.
Comparison of three monoclonal antibodies for
immunoscintigraphy of human colon carcinoma in
nude mice
J. Gretarsdottir', E. Forssell', L. Jacobsson',
S. Mattsson', S.B. Holmberg2, L. Hafstr6m2,
L. Lindholm3, B. Karlsson4 & 0. Nilsson4
Departments of 'Radiation Physics, 2Surgery,
3Medical Microbiology and 4Neurochemistry,
University ofGothenburg, Sweden.
The monoclonal antibodies C241, C242 and C151,
reacting with different epitopes of a carcinoma-
associated glycoprotein, Canag, have been used for
experimental immunoscintigraphy. C241 reacts with
Si-Le'. All MAbs are of the isotype IgGI.
The MAbs were iodinated with 131I, using the
iodogen method. Human colon carcinoma was
inoculated into nude mice. The animals were
injected with 2.5-3.0pg Mab i.v., corresponding to
an activity of 0.5-0.8 MBq. Gamma camera images
were registered in the period 1-144h after injection.
Blood samples were drawn at different times.
Plasma components were separated by exclusion
chromatography and the activity in the various
fractions was measured. The activity concentration
in tumour and organs was measured after the
animals were sacrificed.
Twnour/blood ratio at
MAb Id 3d 6d
C241 0.3-0.9 0.2-1.6 0.2-0.7
(0.5) (0.5) (0.6)
C242 0.3-0.9 0.5-3.2 0.4-1.1
(0.5) (0.7) (0.4)
C151 0.5-0.7 0.6-1.0
(0.6) (0.7)554 ABSTRACTS OF ORAL PRESENTATIONS
Tumour/muscle ratio at
MAb Id 3d 6d
C241 0.3-5.7 0.7-9.4 1.6-4.2
(2.1) (3.5) (3.6)
C242 2.3-4.9 4.2-9.5 0.2-5.5
(3.6) (5.1) (2.5)
C151 5.1-8.6 3.4-10.9
(5.8) (6.9)
Antibody-dependent cellular cytotoxicity against
gliomas: A tracer study using the avidin-biotin
system
T. Bilzer & S. Aumann
Institute of Veterinary Pathology, University of
Munich, FRG.
Monoclonal antibodies (Mab) of IgG2, isotype
raised against membrane components of an
experimental glioma have been used for directing
antibody-dependent cellular cytotoxicity against
experimental gliomas. Mouse peritoneal macro-
phages were coupled in vitro with biotinilated Mab
and administered i.p. in athymic, macrophage-
depleted mice bearing s.c. tumour grafts. At 24, 48,
72 and 96h after injection tumour tissue was
investigated by post-embedding staining adding
avidin-biotin-alkaline phosphatase and avidin-
biotin-ferritin, respectively.
After 24h Mab-macrophages were detectable in
intratumour blood vessels and first signs of peri-
vascular infiltration occurred. From 48h to 96h
widespread distribution of Mab-macrophages in the
tumour tissue developed. Electron microscopically,
Mab-macrophages could be found in close
apposition to glioma cells contacting them over
Mab-coated areas. Target cell death seemed to be a
common event, mostly in the mode of apoptosis.
(Supported by the K.L. Weigand Foundation
(54773).)
Antibody-guided detection of primary meduliary
carcinoma by means of I"'In labelled anti-CEA
monocional antibody: A case report
G. Moscatelli, M. Agostini, S. Benini, G. Paganelli,
P. Riva & V. Tison
Istituto Oncologico Romagnolo, 47023 Cesena, Italy
The MoAb employed in this study was an IgGi
directed against the CEA peptide chain.
Since we found 60% positive staining in a large
number of fresh frozen tissue sections from breast
carcinoma, we decided to study by external body
scintigraphy a patient who had already undergone
operation for breast carcinoma.
This 40 year old patient had high levels of
circulating CEA without clinical or radiological
evidence of disease. The antibody-guided scan using
1IIIn-labelled F(ab')2 fragments of the MoAb
mentioned above, detected an unsuspected
accumulation area of radioactivity located in the
thyroid, corresponding to a node of the gland: a
fine needle aspiration showed a medullary
carcinoma.
No positive scan was obtained when we injected,
as negative control, a non-specific antibody directed
against melanoma. This finding seems promising in
the use of immunoscintigraphy for the follow-up of
patients with thyroid medullary cancer.
The pre-operative detection of axiliary lymph node
metastasis in breast cancer patients using
1-123-labelled monoclonal antibodies
R. Mandeville, N. Pateisky, K. Philipp, E. Kubista,
F. Dumas & B. Grouix
Immunology Research Centre, Institut Armand-
Frappier, University ofQuebec, LDR, Canada and
Ist Department ofObstetrics and Gynaecology,
University of Vienna, Austria.
In an attempt to improve the accuracy of pre-
operative detection of axillary lymph node
metastases, we have used a radiolabelled mono-
clonal antibody designated 3C6F9 and directed
against a glycoprotein of 37,000mol. wt found on
the surface of primary and metastatic breast
tumours. The 3C6F9 immunoglobulin (IgG2a) was
purified, radiolabelled with 1-123 and used for
gamma-scintigraphy in 9 patients with the clinical
diagnosis of breast tumours. Each patient received
1 mCi (specific activity 2mCi mg - of antibody) as
a s.c. injection into the finger webs between the 2nd
and the 3rd fingers of both hands, i.e. the healthy
side serving as a control for the affected side.
Images of lymph node metastases were visible 18 to
24h after injection of the antibody and without the
aid of background substration manipulations.
Seven of the 9 patients studied were positive by
scanning and 6 showed positive lymph node
involvement by histopathology (true positive, 86%).
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axilla and were subsequently found to be free of
lymph node metastases (true negative, 100%). Only
one patient with a positive scan had no lymph node
metastases on serial sectioning (false positive, 14%).
These results given an overall specificity of RIS of
88% and demonstrate that 3C6F9 localises prefer-
entially in affected axillary lymph node compared
to normal lymph nodes. These preliminary results
support the hope that this non-invasive approach
can be used to image metastatic tumour deposits in
axillary lymph node and can therefore have
important implications in the diagnosis, staging and
monitoring of breast cancer patients.
The detection of c-myc oncogene product in patients
with solid tumours
S. Chan, G. Evan & K. Sikora
Ludwig Institutefor Cancer Research, MRC Centre,
Hills Road, Cambridge, UK.
We have studied the utility of the c-myc oncogene
product as a tumour marker using a set of mono-
clonal antibodies raised against synthetic peptides
constructed from sequence data of the human
c-myc oncoprotein. Antibodies Mycl-9E10 and
Mycl-CT14, raised against the C-terminal 32 amino
acids, have been shown to detect specifically the
62,000 dalton c-myc gene product in tumour cells.
Iodine-131 labelled Mycl-CT14 was injected i.v.
into 14 patients with primary lung cancer. There
was selective uptake at the primary tumour site of
12 patients, suggesting a large quantity of the p62-
myc in these areas. The protein is usually found
within the nucleus and it is unlikely that the
antibody can enter this site for binding. It is
probable that the oncoprotein is present in the
extracellular space surrounding the tumour cells as
a result of cellular breakdown. Shed oncogene
product or their metabolites may be detected in the
serum.
Immunoblotting of sera and urine with antibody
Mycl-9E10 consistently revealed a single 40,000
dalton band (p40). Quantitative analysis using
dilution dot immunoblotting demonstrated a
considerable increase in the titre of p40 in the sera
of 51 patients with a wide range of advanced solid
tumours when compared to 17 healthy controls and
50 patients with nonmalignant diseases. Serial
measurement of the p40 titre in 12 patients with
resected colorectal carcinoma shows a gradual
return to normal with a half-life of 7 days. Our
data suggest that p40 may be a useful new marker
for monitoring tumour activity.
Immunoscintigraphy of bone metastases from breast
carcinoma
K.R. Roberts, D. Clarke, M.C. Ward,
J.H. Westwood, V.R. McCready & R.J. Ott
Royal Marsden Hospital and Ludwig Institutefor
Cancer Research, Sutton, Surrey, UK.
The mouse monoclonal antibody 2-94-2 (an IgG3)
was raised against a crude membrane extract from
a metastatic bladder carcinoma. Immunocyto-
chemical staining indicated features related to
epithelial membrane antigen (EMA) antibodies, one
of which (LICR-LON-M8) has been used
successfully to image bone metastases in breast
cancer patients (Rainsbury et al., Lancet, ii, 934,
1983). The usefulness of 2-94-2 for clinical immuno-
scintigraphy in this group of patients was evaluated.
The antibody was conjugated to DTPA, labelled
with IIIIndium and injected i.v. into 8 patients, 7
of whom had previously received chemotherapy.
The immunoscintigraphic results were correlated
with the known sites of metastatic disease, assessed
using a combination of the clinical findings,
histology, MDP bone scans, radiographs and CT
scans. No false positive antibody scans resulted. 2-
94-2 was effective in imaging skull (6/6 patients)
and femoral metastases (8/8) but only imaged 1/6
patients with rib metastases. High radiolabel uptake
by the liver and spleen tended to obscure the lower
thoracic and upper lumbar-regions.
The results indicate that 2-94-2 immunoscinti-
graphy is not adequate by itself for detecting bone
metastases from breast carcinoma; a cocktail of 2-
94-2 and LICR-LON-M8 may be more sensitive in
detecting such lesions.
Selective modification of NMR relaxation time
in human colorectal carcinoma using
gadolinium-DTPA-Mab 19-9 complex. Use of
different Gd-DTPA concentrations/MAb molecule
C. Curtet, J. Bohy, C. Tellier, J.C. Saccavini &
J.F. Chatal
Unite 211, INSERM, Lab. RMN, Nantes and ORIS
Industrie, Saclay, France.
The use of paramagnetic agents for contrast
enhancement may extend the diagnostic potential of
nuclear magnetic resonance imaging (MRI). Mono-
clonal antibody 19-9 (MAb 19-9) against human
colon adenocarcinoma was conjugated with556 ABSTRACTS OF ORAL PRESENTATIONS
gadolinium DTPA (Gd-DTPA) and used as
contrast agent in NMR in an effort to improve
target selectivity. Our previous work had indicated
that Gd-DTPA MAb 19-9 in solution decreased T,
relaxation ofwater protons at 90MHz and that this
effect was greater than in Gd-DTPA solutions. T,
relaxation time at 90 MHz measured in tumours
removed from nude mice, 24h after injection of
Gd-DTPA-MAb 19-9 (Gd 0.08mmolkg-1, 15
DTPA/MAb) decreased significantly (15%) as
compared with the control group.
An attempt was made in the present work to
enhance gadolinium concentration by coupling 16,
25 and 50 DTPA/MAb. Immunoreactivity was
tested against cell lines in culture (human colorectal
carcinomas HRT18, SW948; and breast carcinoma
MDA) with 2, 16, 25, 50 DTPA/MAb. Immuno-
reactivity was not affected to 25 DTPA/MAb and
decreased at 50 DTPA/MAb. Pharmacokinetics
were performed with 113Gd-DTPA-73-3 (25
DTPA/MAb); the specific activity was
0.15 pCiig-1 and 8% of the injected doseg-' of
tissue was found at the tumour site without
variation between days 1 and 5. T, relaxation time
was calculated at 20MHz on tumour grafted on
nude mice removed at day 5. After injection of Gd-
DTPA-73-3 (25 DTPA/MAb), 3 MAb concen-
trations were tested (60pM, 30MM, 15pM). There
was respectively a decrease of 22%, 16% and 10%
of the T, compared with the control.
Induction of an 'anti-idiotypic network' as a result of
monoclonal antibody therapy
N.S. Courtnay-Luck"2, A.A. Epenetos' &
M.A. Ritter2
Departments of'Clinical Oncology and
2Immunology, Royal Postgraduate Medical School,
London, UK.
Repeated administration of radiolabelled murine
monoclonal antibodies for the diagnosis and
therapy of some malignant neoplasms results in the
development of an 'anti-idiotypic network'.
Initially, the recipient develops a human anti-
mouse response to antigenic determinants on both
the Fc and, later, F(ab')2 components of the
murine immunoglobulin of which a component is
anti-idiotypic (anti-Id,). With further administra-
tion an anti-Id2 antibody is produced which
possesses the 'internal image' of the tumour antigen
and consequently recognises the same antigen as the
injected murine monoclonal. These antibodies can
therefore be described as anti-tumour.
Formation of immune complexes and the subsequent
increase in clearance rate of radiolabel
G. Hooker' & N. Courtnay-Luck2
'Department ofMedical Physics, Royal
Postgraduate Medical School, London and
2Department ofImmunology, Royal Postgraduate
Medical School ofLondon and Imperial Cancer
Research Fund, London WC2, UK.
More than 30 patients have been treated thus far
for malignant disease by systemic or direct i.p.
injections of '3II-labelled monoclonal antibodies
(range 30-150mCi 131I, specific activity
10mCimg-I murine immunoglobulin). In each
case the human anti-mouse response, the total
radioiodine content of peripheral blood and total
body radiation were measured. Patients receiving
two or more treatments have shown a markedly
more rapid clearance of radiolabel and this has
been accompanied by an elevated anti-murine
serum immunoglobulin. The formation of immune
complexes is suggested as an explanation for this
phenomenon since it is well established that they
are cleared more rapidly than uncomplexed soluble
antigen. The observed change in kinetics associated
with second and subsequent treatments has implica-
tions with regard to the dosimetry and effectiveness
of a regime requiring more than one treatment.
The organisers wish to acknowledge the support of the
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Industries, Serotec, Lederle & the Imperial Cancer
Research Fund.